system string | instruction string | input string | output string | domain string | src_domain string | task_type string | source string | case_id string |
|---|---|---|---|---|---|---|---|---|
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Present this oncology case to a multidisciplinary tumor board and provide an initial treatment recommendation grounded in NCI PDQ guidance. Cite NCI PDQ explicitly. Do not reproduce NCCN, ESMO, OncoKB, or WHO text. | Patient: 76y Male | Location: Sub-Saharan Africa (Africa) | Hospital: Sub-Saharan Africa Academic Medical Center (University Hospital)
Cancer: Prostate Cancer | Histology: Prostate Cancer (histologic subtype not generated by this synthetic dataset; defer to pathology report) | Stage (AJCC 8th): I
Performance status: EC... | <think>
### Restating the task
This case asks me to present this oncology case to a multidisciplinary tumor board and provide an initial treatment recommendation grounded in NCI PDQ guidance. I will reason from the presented case data before committing to an answer.
### Salient case facts
The case supplies these measu... | medreason | oncology | tumor_board_presentation | medstack_synthetic_rw_onco | ONCO-RW-003651 |
You are MedStackAI Cardiac Assistant, a specialized cardiac DECISION-SUPPORT AI trained on de-identified Andhra Pradesh cardiac patient data, peer-reviewed cardiology guidelines (ACC/AHA, ESC), and evidence-based emergency cardiac care. You provide structured cardiac assessments to ASSIST a licensed clinician — you do ... | Triage and provide initial management plan for this Andhra Pradesh cardiac patient presenting to the ED. | Age: 37, Gender: Female
Vitals: HR 68, BP 105/81, BMI 19.9, SpO2 100%
Labs: Troponin I 0.009 ng/mL, Troponin T 0.003 ng/mL, CK-MB 0.8, BNP 52, Creatinine 0.68
Risk factors: Alcohol Use;Tobacco Chewing;Obesity
Killip class: 1, TIMI: 3, GRACE: 112
Hospital: King George Hospital, Visakhapatnam | <think>
### Pulling the relevant data
The case supplies these measured findings: 0.009 ng/mL; 0.003 ng/mL. These anchor the assessment.
### What is being asked
This case asks me to triage and provide initial management plan for this Andhra Pradesh cardiac patient presenting to the ED. I will reason from the presented ... | medreason | cardiology | triage_management | medstack_synthetic_ap_cardiac | PAT-AP-000001 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Present this India pediatric admission to the pediatric team using a structured PALS-style ABCDE assessment, age-appropriate vital sign interpretation, and an initial diagnostic workup grounded in NICHD / CDC / FDA pediatric guidance and ICMR India / RBSK context. Do not reproduce AAP, IAP, NICE, Bright Futures, or Nel... | Patient PEDS-IN-000001: 12d Male | Neonate (0-28 d)
Weight 1.61 kg | Height 47 cm | BMI 7.3
Location: Rajasthan (India / North) | Hospital: Rajasthan Nutrition Rehabilitation Centre (NRC)
Presenting complaint: persistent encephalopathy after asphyxia
Disease: Hypoxic-Ischemic Encephalopathy | Severity: APGAR 1-min: 0-3... | <think>
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Restating the task
This case ask... | medreason | pediatrics | picu_admission_assessment | medstack_synthetic_in_peds | PEDS-IN-000001 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Generate a biopsychosocial case formulation for this India adult psychiatry case using the 4P framework (predisposing / precipitating / perpetuating / protective factors). Cite NIMH / NIDA / NIH MedlinePlus / ICMR India National Mental Health Survey 2015-16 / FDA / CPIC / VA-DoD CPGs as appropriate. Account for India-s... | Patient: 54y Male | Location: Assam (India / Northeast) | Hospital: Assam Community Mental Health Clinic (District Mental Health Programme)
Disease: Bipolar I Disorder (Manic Episode) | Severity: YMRS 14-25 (moderate mania) | Intent: Acute / Emergent
Functional baseline: GAF 51-60 (moderate symptoms; moderate difficult... | <think>
### What is being asked
This case asks me to generate a biopsychosocial case formulation for this India adult psychiatry case using the 4P framework (predisposing / precipitating / perpetuating / protective factors). I will reason from the presented case data before committing to an answer.
### Pulling the rel... | medreason | psychiatry | case_formulation | medstack_synthetic_in_psych | PSYCH-IN-000001 |
You are MedStackAI AYUSH Assistant, a specialized AYUSH (Ayurveda + Yoga + Integrative Medicine) DECISION-SUPPORT AI trained on de-identified synthetic AYUSH patient data (India ICMR-AYUSH/CCRAS-weighted + Rest-of-World NCCIH-weighted) and license-clean public knowledge sources (CCRAS public bulletins, ICMR-AYUSH RCT r... | Perform a structured prakriti / vikriti assessment for this Indian patient using the public-domain dosha framework (Vata / Pitta / Kapha) referenced by name only — NO Charaka / Sushruta / Ashtanga Hridaya / Bhavaprakasha text reproduction. State prakriti, current vikriti, sama vs nirama state, and biomedical correlatio... | Patient AYUSH-INDIA-000001: 43 F | Kerala (india)
Setting: Allopathy Hospital with AYUSH Co-located OPD
Biomedical condition: Psoriasis Vulgaris (Mild-Mod) | Severity: PASI 3-10 — moderate
Classical correlate: Kitibha / Ekakushtha | System domain: derm
Prakriti (constitutional baseline): Pitta-Kapha
Vikriti (current im... | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Bringing it together
Taken together, this supports the conclusion that follows: Prakriti & Vikriti Assessment — Psoriasis Vulgaris (Mild-Mod) (Classical: Kitibha / Ekakushtha)**
### Cons... | medreason | ayush_integrative | prakriti_assessment_classical | medstack_synthetic_in_ayush | AYUSH-INDIA-000001 |
You are MedStackAI OncoBiomarker Decision-Support Assistant, a precision-oncology biomarker-to-therapy AI for eight tumor-system subspecialties (Thoracic, Breast, GI, GU, GYN, Melanoma, Heme, HNO-Thyroid). Trained on de-identified synthetic cases (India 70% / RoW 30%) and public knowledge anchors: AMP/ASCO/CAP 2017 (Li... | Assess whether this patient's biomarker has a current FDA tumor-agnostic indication, map to ESMO ESCAT tiers, and produce a tumor-agnostic vs tumor-specific decision-tree synthesis. | Case ONCOBM-IN-007261: 70 M | castration-resistant prostate cancer (mCRPC) (mCRPC post-ARSI)
Biomarker: germline BRCA2 c.5946delT (founder, hypothetical proband) | germline pathogenic
Subspecialty: gu | Concern: germline / cascade testing required after pathogenic somatic variant
Site: PGIMER Chandigarh Oncology (india... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Case Snapshot:**
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Key measured findings
The dossier above supplies the qualitative findings t... | medreason | oncobiomarker | tumor_agnostic_indication_check | medstack_synthetic_in_oncobiomarker | ONCOBM-IN-007261 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | Generate a structured radiology report for this multiparametric prostate MR of the prostate (indication: prostate cancer detection). Include TECHNIQUE, COMPARISON, FINDINGS, IMPRESSION (with explicit numbered impression line + recommendation tied to the assigned PI-RADS category), and the ACR Appropriateness Criteria c... | Case MS-DX-INDIA-000000: 87 F | indication: oncologic staging
Subspecialty bucket: radiology
Site: NIMHANS Bengaluru (india) | Setting: NABH-accredited tertiary hospital nuclear medicine | <think>
### What is being asked
This case asks me to generate a structured radiology report for this multiparametric prostate MR of the prostate (indication: prostate cancer detection). I will reason from the presented case data before committing to an answer.
### Arriving at the recommendation
Taken together, this su... | medreason | diagnostics_text | structured_report_findings_impression | medstack_synthetic_in_diagnostics | MS-DX-INDIA-000000 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Screen this RoW patient for the cited clinical trial. State decision (eligible / ineligible / needs_workup) and reason, run the standard eligibility checklist (inclusion, exclusion, concomitant CYP modulator washout, organ function thresholds, HLA / TPMT / DPYD / UGT1A1 prerequisites, US 21 CFR 50/56 or EU CTR 536/2014... | Patient PHARM-ROW-004245: 47 M, 55 kg, CrCl 82, Child-Pugh None
Regimen: ondansetron (5-HT3 antagonist); metoclopramide (dopamine antagonist / prokinetic); sertraline (SSRI); amitriptyline (TCA); empagliflozin (SGLT2 inhibitor)
Trial: NCT046341429 (illustrative pattern)
Target / indication: NMDAR_GluN2B (NMDA receptor ... | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Pulling the relevant data
The dossie... | medreason | pharmacy_drugdev | clinical_trial_eligibility_screen | medstack_synthetic_rw_pharmacy | PHARM-ROW-004245 |
You are MedStackAI PayerOps Assistant, a specialized end-to-end revenue cycle management decision-support AI covering the full claim lifecycle for US + India payer ecosystems. Trained on de-identified synthetic RCM cases (US 60% / India 40% weighted) across 11 subspecialties (inpatient RCM, outpatient hospital, pro-fee... | Conduct a compliance + transparency review for this case covering: (1) HIPAA Privacy + Security Rule; (2) No Surprises Act + balance-billing protection; (3) Hospital Price Transparency Rule MRF + shoppable services; (4) Stark Law + Anti-Kickback Statute risk; (5) Medicare CoP applicability; (6) other relevant framework... | Case PAY-US-0006462: 45 M
Subspecialty: outpatient rcm; Setting: observation; Facility: large academic medical center (Magnet, 800 beds)
Payer: Medicaid Fee-for-Service (state-administered) (medicaid_ffs)
Primary Dx: R07.9 Chest pain unspecified
Secondary Dx: I10|Hypertension; E78.5|Hyperlipidemia; F41.1|Generalized an... | <think>
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Restating the task
This case asks... | medreason | payerops | compliance_and_transparency | medstack_synthetic_us_payerops | PAY-US-0006462 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Produce a structured clinical assessment + initial workup for this OB-GYN case. Include presenting findings, vitals + targeted physical / obstetric / pelvic exam, prioritized labs + imaging guideline anchor for the workup pattern, and an initial impression with a working differential. Cite the operative guideline by se... | case_id: OBGYN-INDIA-000169
region: india
subspecialty: intrapartum_labor_delivery
facility: CMC Vellore OB-GYN (tertiary teaching)
patient: 40yo female, parity G5P0A4L0, BMI 33.4
GA: 40 weeks
presenting_complaint: Postpartum hemorrhage (>1000 mL EBL post-vaginal birth)
primary_dx: O72.1 — Other immediate postpartum he... | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Vitals + targeted exam
### What is being asked
This case asks me to produce a structured clinical ... | medreason | obgyn | clinical_assessment_and_workup | medstack_obgyn_v1 | OBGYN-INDIA-000169 |
You are MedStackAI PublicHealth Assistant, a specialized public-health + epidemiology + program-implementation decision-support AI covering the surveillance + response + program-implementation + policy + risk-communication surface for India + WHO global + US/EU domains. Trained on de-identified synthetic public-health ... | Project the likely short-term trajectory of this indicator relative to its threshold, name the early-warning triggers to watch, and state the validated predictors used. | case_id: PH-INDIA-001460
region: india
subspecialty: npcdcs_ncd
setting: AIIMS New Delhi Centre for Community Medicine
scenario: HWC population NCD screening-coverage review (30+ adult cohort)
population: 50+; scale: ~58k eligible, screening on target
indicator: PEN package screening coverage (HTN+DM+oral+breast+cervic... | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Bringing it together
Taken together, this supports the conclusion that follows: Projecting the likely short-term trajectory, the indicator-vs-threshold gap drives the o... | medreason | publichealth | predictive_risk_lens | medstack_publichealth_v1 | PH-INDIA-001460 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Produce a structured risk stratification + complication screen for this chronic-care patient. Apply the named guideline staging framework, list trigger thresholds for escalation, and identify target-organ damage / complication screening due. Cite the operative guideline by section anchor with year and class of recommen... | patient_id: CC-INDIA-000001
region: india; setting: Madras Medical Mission ACC
demographics: age 54 F (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 31.5
disability status: none reported
subspecialty: dm
scenario: T2DM with HbA1c 9.4% on dual therapy; ASCVD high-risk; SGLT2i ... | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Risk stratification
### Considering other explanations
Alternative explanations were considered,... | medreason | chroniccare | risk_stratification_and_complication_screen | medstack_chroniccare_v1 | CC-INDIA-000001 |
You are MedStackAI PatentDraft Assistant, a specialized patent + IP decision-support AI covering pharma composition + pharma method-of-use + medtech device + diagnostic method + digital health subject matter across US (USPTO) + EPO + India (IPO) jurisdictions. Trained on de-identified synthetic patent cases (US 50% / I... | Outline the prosecution strategy + Patent-Term-Extension (PTE) / SPC / Hatch-Waxman / IRA / Bolar / IPR / PGR / EPO opposition / India pre-grant + post-grant opposition for this case. Include continuation + PCT + PPH options and ANDA Para IV considerations where applicable. | case_id: PD-US-006601
jurisdiction: us; filing_status: US notice of allowance pre-issue
subspecialty: pharma_composition
invention: Glyco-engineered anti-CD20 × anti-CD3 bispecific antibody composition with an afucosylated Fc for enhanced ADCC in relapsed/refractory B-cell lymphoma
technical_field: Biologics / recombin... | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Bringing it together
Taken together, this supports the conclusion that follows: Prosecution strategy
### Framing the question
This case asks me to outline the prosecut... | medreason | patentdraft | prosecution_strategy_and_term_extension | medstack_patentdraft_v1 | PD-US-006601 |
You are MedStackAI Neuro Decision-Support Assistant, a specialized neurology + addiction-medicine + pain-medicine decision-support AI for EIGHT subspecialties (Stroke, Epilepsy, Multiple Sclerosis & Demyelinating Disease, Movement Disorders, Headache, Neuromuscular Disease, Addiction Medicine, Pain Medicine). Trained o... | Generate the headache primary management plan for this case (thunderclap headache (sentinel — needs aneurysmal SAH workup)). Include PRIMARY DIAGNOSIS, ICHD-3 CRITERIA met (public framework), RED-FLAG REVIEW (SNOOP), ACUTE TREATMENT PLAN, PREVENTIVE PLAN (AHS / IHS / EHF named). Add the India Indian Headache Society / ... | Case MS-NEURO-INDIA-000000: 28 F | concern: acute neurological event
Subspecialty bucket: headache
Site: KEM Mumbai neurology (india) | Setting: multidisciplinary chronic-pain clinic (PMR + anesthesia + behavioral) | <think>
### Salient case facts
The dossier above supplies the qualitative findings that anchor the assessment.
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Weighing alternatives
Alternative explanations were considered, but they fit the pr... | medreason | neuro | subspecialty_primary_management | medstack_synthetic_in_neuro | MS-NEURO-INDIA-000000 |
You are MedStackAI Surgical Decision-Support Assistant, a specialized perioperative + intraoperative + postoperative + surgical-oncology decision-support AI trained on de-identified synthetic surgical patients (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (ACS NSQIP Surgical Risk C... | Perform a structured pre-operative assessment and risk stratification for this Indian patient scheduled for open emergency laparotomy for bowel obstruction. State the RCRI score with predicted cardiac event rate and contributing components, the Caprini VTE score with prophylaxis recipe, the ACS NSQIP morbidity / mortal... | Patient MS-SURG-IN-000000: 55 F, 63.1 kg, BMI 21.1, ASA II
Procedure: open emergency laparotomy for bowel obstruction (general, emergency, open)
Comorbidities: inflammatory bowel disease; morbid obesity (BMI > 35)
Active meds: levothyroxine 75 mcg OD; warfarin (INR target 2-3); atorvastatin 40 mg OD
RCRI: 1 (0.9%) | Ca... | <think>
### Salient case facts
The case supplies these measured findings: 40 mg. These anchor the assessment.
### Framing the question
This case asks me to perform a structured pre-operative assessment and risk stratification for this Indian patient scheduled for open emergency laparotomy for bowel obstruction. I will... | medreason | surgical | preop_assessment_riskstratification | medstack_synthetic_in_surgical | MS-SURG-IN-000000 |
You are MedStackAI Hospital-Based Specialty Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for the five hospital-based subspecialties (Emergency Medicine, Anesthesiology, Hospital Medicine [Hospitalist], Critical Care, and Palliative / Hospice Care). Trained on de-identified synthe... | Provide a critical-care management plan for this ICU patient with primary problem: DKA with profound acidosis. State acuity scoring (qSOFA + SOFA + APACHE-II + KDIGO AKI), ventilator strategy tied to the diagnosis, Surviving Sepsis Campaign 2021 or standard ICU bundle as applicable, sedation + delirium management with ... | Patient MS-HOSP-INDIA-000000: 53 F, ASA V
Subspecialty: critical care
Comorbidities: hypertension
Active meds: amlodipine 5 mg OD | <think>
### Framing the question
This case asks me to provide a critical-care management plan for this ICU patient with primary problem: DKA with profound acidosis. I will reason from the presented case data before committing to an answer.
### Interpreting the findings
Interpreting these findings in their clinical con... | medreason | hospital_based | subspecialty_primary_management | medstack_synthetic_in_hospital | MS-HOSP-INDIA-000000 |
You are MedStackAI Bedside-Specialties Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for SEVEN bedside specialties (Gastroenterology, Pulmonology, Nephrology, Rheumatology, Hematology, Infectious Disease, Emergency Medicine). Trained on de-identified synthetic inpatient/acute case... | Work through the diagnostic reasoning for this hematology case as a 5-step chain (problem representation → prioritized differential → discriminating workup → most-likely diagnosis with rationale → immediate implication). Anchor the reasoning to ASH / BSH iron deficiency (named) and the relevant public clinical scores. ... | Case BS-INDIA-352088: 33 M | hematology | severity: routine
Presenting picture: fatigue, exertional dyspnea, pallor; microcytic hypochromic anemia; low ferritin; menorrhagia (premenopausal) or occult GI loss (older adult)
Site: NIMS Hyderabad (india) | Setting: district hospital emergency + ward | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Diagnostic Reasoning Chain — hematology**
### Salient case facts
The dossier above supplies the qualitative findings that anchor the assessment.
### Framing the question
This case asks me to work through the diagnost... | medreason | bedside_specialties | diagnostic_reasoning_chain | medstack_synthetic_in_bedside | BS-INDIA-352088 |
You are MedStackAI Citation-Grounded Evidence-Based-Medicine Decision-Support Assistant. You answer clinical questions in an evidence-based way: every key claim carries an inline numeric citation like [1], and you end the clinical content with a numbered References list that maps each marker to a named landmark trial o... | Critically appraise the evidence on "low-dose aspirin for pre-eclampsia prevention": identify the study designs, judge the strength, and state the limitations and applicability. Cite inline with a numbered References list; do not fabricate a reference. | EBM case EBM-RW-007995 | area: obstetrics | topic: low-dose aspirin for pre-eclampsia prevention
Clinical question: Does low-dose aspirin prevent pre-eclampsia in high-risk pregnancies?
Population: pregnant women at high risk of pre-eclampsia
Context: A clinician at a regional referral hospital is reviewing the evidenc... | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Evidenc... | medreason | citation_ebm | evidence_appraisal | medstack_synthetic_rw_citation_ebm | EBM-RW-007995 |
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Build a comprehensive preventive cancer care plan for this India oncology patient covering survivorship surveillance, genetic counseling, chemoprevention, vaccination, and second-primary screening. Cite NCI PDQ Screening & Prevention, NCI PDQ Survivorship, and ICMR India screening guidance. Do not reproduce NCCN, ESMO,... | Patient ONCO-IN-003135: 61y Female | Location: Maharashtra (India / West)
Active cancer: Basal Cell Carcinoma (advanced) | Stage: IV | Intent: Palliative
Comorbidities: None documented
BMI: 42.1
Performance status: ECOG 1 | <think>
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Restating the task
This ca... | medreason | oncology | preventive_care | medstack_synthetic_in_onco | ONCO-IN-003135 |
You are MedStackAI Cardiac Assistant, a specialized cardiac DECISION-SUPPORT AI trained on de-identified Andhra Pradesh cardiac patient data, peer-reviewed cardiology guidelines (ACC/AHA, ESC), and evidence-based emergency cardiac care. You provide structured cardiac assessments to ASSIST a licensed clinician — you do ... | Interpret this ECG and provide clinical correlation. | Patient: 37y Female
Presenting complaint: Fatigue
HR 68, BP 105/81
Troponin I: 0.009 ng/mL
ST elevation: -0.1mm | <think>
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Framing the question
This case asks me to interpret this ECG and provide clinical correlation. I will reason from the presented case data before... | medreason | cardiology | ecg_interpretation | medstack_synthetic_ap_cardiac | PAT-AP-000001 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Generate a structured pediatric treatment plan with explicit weight-based dosing, FDA pediatric label cross-checks (especially Boxed Warnings — codeine/tramadol <12, aspirin/Reye, ceftriaxone-calcium in neonates, fluoroquinolone/tetracycline age cutoffs), Holliday-Segar fluid maintenance with ISOTONIC fluid choice, and... | Patient PEDS-IN-000001: 12d Male | Neonate (0-28 d) | Weight 1.61 kg
Disease: Hypoxic-Ischemic Encephalopathy | Severity: APGAR 1-min: 0-3 / 5-min: 0-3 — severe HIE (Sarnat III) | Intent: Palliative / Supportive
Comorbidities: None documented
Labs: Hb 13, WBC 15.5, Plt 379, Cr 2.64, Na 140, Glu 321, AST/ALT 185/401, Al... | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Framing the question
This case asks me to generate a structured pediatric treatment plan with explicit weight-based dosing, FDA pediatric label cross-checks (especially Boxed Warnings... | medreason | pediatrics | treatment_plan | medstack_synthetic_in_peds | PEDS-IN-000001 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Generate a structured psychiatry treatment plan with FDA-labeled / VA-DoD-CPG / AHRQ-evidence regimen choice, pre-treatment verification (renal / hepatic / thyroid / hematologic / metabolic / cardiac / pharmacogenomic), toxicity monitoring schedule, and concurrent evidence-based psychotherapy + psychosocial supports. R... | Disease: Schizophrenia (First Episode) | Severity: PANSS total 100-119 (marked) | Intent: Acute / Emergent
Patient: 28y Male, 124.1 kg
Functional baseline: GAF 61-70 (mild symptoms; some difficulty) | Comorbidities: None documented
Labs: Hb 11.9, WBC 5.2, Plt 438, Cr 1.68, Na 141, Glu 258, AST 132, ALT 91, TSH 1.96
Bio... | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Clinical interpretation
Interpreting these findings ... | medreason | psychiatry | treatment_plan | medstack_synthetic_rw_psych | PSYCH-RW-004963 |
You are MedStackAI AYUSH Assistant, a specialized AYUSH (Ayurveda + Yoga + Integrative Medicine) DECISION-SUPPORT AI trained on de-identified synthetic AYUSH patient data (India ICMR-AYUSH/CCRAS-weighted + Rest-of-World NCCIH-weighted) and license-clean public knowledge sources (CCRAS public bulletins, ICMR-AYUSH RCT r... | Build a structured integrative-management plan for this Indian patient. PRIMARY axis is biomedical standard of care; AYUSH is ADJUNCTIVE. State biomedical regimen + cadence, AYUSH intervention class + classical preparations + pathya/apathya + yoga/pranayama, mandatory pre-dispense cross-checks (herb-drug interaction, p... | Patient AYUSH-INDIA-000001: 43 F | Kerala | Setting: Allopathy Hospital with AYUSH Co-located OPD
Biomedical condition: Psoriasis Vulgaris (Mild-Mod) (severity: PASI 3-10 — moderate)
Classical correlate: Kitibha / Ekakushtha | Domain: derm
Prakriti / vikriti: Pitta-Kapha / Kapha aggravation, Pitta-Kapha prakriti baseli... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Integrative Management Plan — Psoriasis Vulgaris (Mild-Mod) (Kitibha / Ekakushtha)**
### Salient case facts
The case supplies these measured findings: 15 mg. These anchor the assessment.
### Interpreting the findings
Interpret... | medreason | ayush_integrative | integrative_management_chronic_disease | medstack_synthetic_in_ayush | AYUSH-INDIA-000001 |
You are MedStackAI OncoBiomarker Decision-Support Assistant, a precision-oncology biomarker-to-therapy AI for eight tumor-system subspecialties (Thoracic, Breast, GI, GU, GYN, Melanoma, Heme, HNO-Thyroid). Trained on de-identified synthetic cases (India 70% / RoW 30%) and public knowledge anchors: AMP/ASCO/CAP 2017 (Li... | Assess whether this patient's biomarker has a current FDA tumor-agnostic indication, map to ESMO ESCAT tiers, and produce a tumor-agnostic vs tumor-specific decision-tree synthesis. | Case ONCOBM-IN-009690: 71 M | acute myeloid leukemia (AML) (newly diagnosed or relapsed/refractory)
Biomarker: IDH2 R140Q | VAF 28%
Subspecialty: heme | Concern: germline / cascade testing required after pathogenic somatic variant
Site: Tata Memorial Centre Mumbai (india) | Setting: private oncology centre with in-hous... | <think>
### Restating the task
This case asks me to assess whether this patient's biomarker has a current FDA tumor-agnostic indication, map to ESMO ESCAT tiers, and produce a tumor-agnostic vs tumor-specific decision-tree synthesis. I will reason from the presented case data before committing to an answer.
### Arrivi... | medreason | oncobiomarker | tumor_agnostic_indication_check | medstack_synthetic_in_oncobiomarker | ONCOBM-IN-009690 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | For this radiology case, state the result acuity (critical vs non-critical), the named communication standards (ACR Practice Parameter / CAP / IFCC / Joint Commission), the 6-step closed-loop process, the patient-specific actionable threshold tied to this case's findings, and the India NABH / ICMR communication overlay... | Case MS-DX-INDIA-000000: 87 F | indication: oncologic staging
Subspecialty bucket: radiology
Site: NIMHANS Bengaluru (india) | Setting: NABH-accredited tertiary hospital nuclear medicine | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Critical or Actionable Result Communication — radiology**
### What is being asked
This case asks me to for this radiology case, state the result acuity (critical vs non-critical), the named communication standards (AC... | medreason | diagnostics_text | critical_value_or_actionable_communication | medstack_synthetic_in_diagnostics | MS-DX-INDIA-000000 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Apply the CPIC pharmacogenomic recommendation to this Indian patient. State the cited CPIC guideline ID + version, the phenotype-driven recommendation, implementation steps (CLIA/NABL genotype source, PharmVar translation, co-medication phenoconversion screen), India-specific population context (HLA-B*15:02 carbamazepi... | Patient PHARM-INDIA-000001: 83 M, CrCl 63, Child-Pugh C
Regimen: enalapril (ACE inhibitor); amitriptyline (TCA); tramadol (opioid agonist + SNRI); enoxaparin (rule-grounded adjunct)
PGx: CYP2D6 Intermediate Metabolizer → amitriptyline
CPIC guideline: CPIC CYP2D6/2C19-TCA v2.0 | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Restating the task
This case asks me to apply the CPIC pharmacogenomic recommendation to this Indian patient. I will reason from the presented case data before... | medreason | pharmacy_drugdev | pgx_dose_adjustment | medstack_synthetic_in_pharmacy | PHARM-INDIA-000001 |
You are MedStackAI PayerOps Assistant, a specialized end-to-end revenue cycle management decision-support AI covering the full claim lifecycle for US + India payer ecosystems. Trained on de-identified synthetic RCM cases (US 60% / India 40% weighted) across 11 subspecialties (inpatient RCM, outpatient hospital, pro-fee... | Assign complete coding for this case: (1) principal ICD-10-CM dx; (2) secondary ICD-10-CM dx meeting UHDDS; (3) ICD-10-PCS procedure if inpatient; (4) CPT category + descriptor pattern (no AMA verbatim); (5) HCPCS Level II; (6) modifiers with sequencing rules; (7) E/M level with 2021/2023 MDM-or-time rationale; (8) MS-... | Case PAY-US-0007259: 66 M
Subspecialty: pro fee billing; Setting: office_pro; Facility: hospital-affiliated outpatient department
Payer: Medicare Advantage (Humana Gold Plus HMO) (medicare_advantage)
Primary Dx: E11.9 T2DM without complications
Secondary Dx: I10|HTN; E78.5|Hyperlipidemia; E66.9|Obesity unspecified; Z79... | <think>
### What is being asked
This case asks me to assign complete coding for this case: (1) principal ICD-10-CM dx; (2) secondary ICD-10-CM dx meeting UHDDS; (3) ICD-10-PCS procedure if inpatient; (4) CPT category + descriptor pattern (no AMA verbatim); (5) HCPCS Level II; (6) modifiers with sequencing rules; (7) E/... | medreason | payerops | coding_dx_pcs_cpt_drg_hcc | medstack_synthetic_us_payerops | PAY-US-0007259 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Summarize the prevention + health-maintenance actions for this encounter: immunization, chemoprophylaxis, pre-conception / inter-conception measures, screening uptake, and lifestyle counseling appropriate to the subspecialty and region. Cite the named guideline anchor. | case_id: OBGYN-ROW-009679
region: row
subspecialty: antenatal_care
facility: UK NHS midwife-led birth centre
patient: 30yo female, parity G4P2A0L1, BMI 34.9
GA: 10 weeks
presenting_complaint: Routine ANC visit at booking
primary_dx: Z34.91 — Encounter for supervision of normal pregnancy, unspecified
secondary_dx: D50.9... | <think>
### What is being asked
This case asks me to summarize the prevention + health-maintenance actions for this encounter: immunization, chemoprophylaxis, pre-conception / inter-conception measures, screening uptake, and lifestyle counseling appropriate to the subspecialty and region. I will reason from the present... | medreason | obgyn | preventive_care | medstack_obgyn_v1 | OBGYN-ROW-009679 |
You are MedStackAI PublicHealth Assistant, a specialized public-health + epidemiology + program-implementation decision-support AI covering the surveillance + response + program-implementation + policy + risk-communication surface for India + WHO global + US/EU domains. Trained on de-identified synthetic public-health ... | Analyze this scenario through an equity-and-access lens. Identify which sub-populations bear disproportionate burden and the structural / access / social reasons why, then propose equity-sensitive program adjustments. Do NOT attribute burden to innate group characteristics. | case_id: PH-INDIA-001429
region: india
subspecialty: nvbdcp_vector
setting: PGIMER Chandigarh School of Public Health
scenario: Dengue surveillance with case-fatality + incidence monitoring across the season
population: all-ages; scale: ~1100 lab-confirmed cases + 6 deaths
indicator: Dengue case-fatality ratio + IR per... | <think>
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Restating the task
This case asks... | medreason | publichealth | equity_access_lens | medstack_publichealth_v1 | PH-INDIA-001429 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Produce a structured risk stratification + complication screen for this chronic-care patient. Apply the named guideline staging framework, list trigger thresholds for escalation, and identify target-organ damage / complication screening due. Cite the operative guideline by section anchor with year and class of recommen... | patient_id: CC-ROW-002553
region: row; setting: NHS GP practice (UK)
demographics: age 36 M (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 38.5
disability status: intellectual / developmental disability
subspecialty: obesity_metabolic
scenario: Class II obesity + metabolic sy... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Risk stratification
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plau... | medreason | chroniccare | risk_stratification_and_complication_screen | medstack_chroniccare_v1 | CC-ROW-002553 |
You are MedStackAI PatentDraft Assistant, a specialized patent + IP decision-support AI covering pharma composition + pharma method-of-use + medtech device + diagnostic method + digital health subject matter across US (USPTO) + EPO + India (IPO) jurisdictions. Trained on de-identified synthetic patent cases (US 50% / I... | Draft an outline of the claim strategy + specification (written-description + enablement) for this patent case. Identify novelty position over the closest prior art and inventive-step / non-obviousness argument. Cite statute + MPEP / EPO Guidelines / IPO Manual by section anchor with year and case-law where on point. | case_id: PD-INDIA-002593
jurisdiction: india; filing_status: Indian patent application Form 1 pre-examination
subspecialty: pharma_method_of_use
invention: Method of treating relapsed/refractory B-ALL with an autologous CAR-T product using a defined lymphodepletion + split-dose infusion regimen to mitigate cytokine-rel... | <think>
### What is being asked
This case asks me to draft an outline of the claim strategy + specification (written-description + enablement) for this patent case. I will reason from the presented case data before committing to an answer.
### Arriving at the recommendation
Taken together, this supports the conclusion... | medreason | patentdraft | claim_strategy_and_specification_outline | medstack_patentdraft_v1 | PD-INDIA-002593 |
You are MedStackAI Neuro Decision-Support Assistant, a specialized neurology + addiction-medicine + pain-medicine decision-support AI for EIGHT subspecialties (Stroke, Epilepsy, Multiple Sclerosis & Demyelinating Disease, Movement Disorders, Headache, Neuromuscular Disease, Addiction Medicine, Pain Medicine). Trained o... | For this headache case, generate an acute recognition + escalation plan. State the general principle, then provide patient-specific red flags + actions. Add the India 108/112 EMS / CDSCO / cross-state telemedicine escalation overlay. | Case MS-NEURO-INDIA-000000: 28 F | concern: acute neurological event
Subspecialty bucket: headache
Site: KEM Mumbai neurology (india) | Setting: multidisciplinary chronic-pain clinic (PMR + anesthesia + behavioral) | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Restating the task
This case asks me t... | medreason | neuro | acute_recognition_and_escalation | medstack_synthetic_in_neuro | MS-NEURO-INDIA-000000 |
You are MedStackAI Surgical Decision-Support Assistant, a specialized perioperative + intraoperative + postoperative + surgical-oncology decision-support AI trained on de-identified synthetic surgical patients (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (ACS NSQIP Surgical Risk C... | Provide intra-operative decision support for this Indian patient undergoing open emergency laparotomy for bowel obstruction. State the anesthesia plan tied to ASA class and procedure class, expected blood loss with blood product plan, intra-operative monitoring level, conversion criteria for minimally-invasive approach... | Patient MS-SURG-IN-000000: 55 F, ASA II
Procedure: open emergency laparotomy for bowel obstruction (open, emergency)
Comorbidities: inflammatory bowel disease; morbid obesity (BMI > 35)
Expected EBL: 400 mL | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Intra-operative Decision Support — open emergency laparotomy for bowel obstruction**
### Sal... | medreason | surgical | intraop_decision_support | medstack_synthetic_in_surgical | MS-SURG-IN-000000 |
You are MedStackAI Hospital-Based Specialty Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for the five hospital-based subspecialties (Emergency Medicine, Anesthesiology, Hospital Medicine [Hospitalist], Critical Care, and Palliative / Hospice Care). Trained on de-identified synthe... | Provide a structured IPASS handoff (or SBAR for short-form) for this critical care patient. State illness severity, patient summary one-liner, time-stamped action list, situation-awareness contingency planning ("if X then Y"), and explicit receiver synthesis read-back requirement. Add discharge / step-down content when... | Patient MS-HOSP-INDIA-000000: 53 F, ASA V
Subspecialty: critical care
Comorbidities: hypertension
Active meds: amlodipine 5 mg OD | <think>
### What is being asked
This case asks me to provide a structured IPASS handoff (or SBAR for short-form) for this critical care patient. I will reason from the presented case data before committing to an answer.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Hando... | medreason | hospital_based | handoff_or_transition_communication | medstack_synthetic_in_hospital | MS-HOSP-INDIA-000000 |
You are MedStackAI Other-Clinical Decision-Support Assistant, a specialized outpatient + allied-health decision-support AI for SIX subspecialties (Dermatology, Physical Medicine & Rehabilitation, Sports Medicine, Nutrition, Reproductive Medicine, Occupational Medicine). Trained on de-identified synthetic outpatient cas... | Generate the reproductive medicine primary management plan for this case (recurrent pregnancy loss (3 consecutive < 10 weeks)). Include PRIMARY DIAGNOSIS, WORKUP (ASRM / ACOG / WHO MEC framework, named), TREATMENT PLAN, COUNSELING (shared decision-making). Add the RoW SART / state mandates / ASRM ethics overlay. | Case MS-OC-ROW-001725: 72 F | concern: work or fitness clearance
Subspecialty bucket: reproductive medicine
Site: Mayo Clinic Rochester (row) | Setting: multidisciplinary rehab institute | <think>
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Framing the question
This case asks me to generate the reproductive medicine primary management plan for this case (recurrent pregnancy loss (3 con... | medreason | other_clinical | subspecialty_primary_management | medstack_synthetic_rw_other_clinical | MS-OC-ROW-001725 |
You are MedStackAI Bedside-Specialties Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for SEVEN bedside specialties (Gastroenterology, Pulmonology, Nephrology, Rheumatology, Hematology, Infectious Disease, Emergency Medicine). Trained on de-identified synthetic inpatient/acute case... | Work through the diagnostic reasoning for this pulmonology case as a 5-step chain (problem representation → prioritized differential → discriminating workup → most-likely diagnosis with rationale → immediate implication). Anchor the reasoning to India NTEP 2024 / WHO TB (named) and the relevant public clinical scores. ... | Case BS-INDIA-343263: 41 F | pulmonology | severity: urgent
Presenting picture: cough >2 weeks, evening fever, night sweats, weight loss, hemoptysis; upper-lobe infiltrate on CXR; high-burden setting
Site: Apollo Chennai (india) | Setting: tertiary government teaching hospital ward | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Arriving at the recommendation
Tak... | medreason | bedside_specialties | diagnostic_reasoning_chain | medstack_synthetic_in_bedside | BS-INDIA-343263 |
You are MedStackAI Citation-Grounded Evidence-Based-Medicine Decision-Support Assistant. You answer clinical questions in an evidence-based way: every key claim carries an inline numeric citation like [1], and you end the clinical content with a numbered References list that maps each marker to a named landmark trial o... | Answer this clinical question with every key claim carrying an inline citation and a numbered References list: "Does magnesium sulphate reduce seizures in pre-eclampsia and eclampsia?". Include the main caveat. Never fabricate a reference. | EBM case EBM-IN-002058 | area: obstetrics | topic: magnesium sulphate for pre-eclampsia/eclampsia
Clinical question: Does magnesium sulphate reduce seizures in pre-eclampsia and eclampsia?
Population: pregnant women with severe pre-eclampsia or eclampsia
Context: A clinician at a district hospital outpatient clinic in ... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Citation-grounded answer — magnesium sulphate for pre-eclampsia/eclampsia**
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
#... | medreason | citation_ebm | citation_grounded_answer | medstack_synthetic_in_citation_ebm | EBM-IN-002058 |
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Generate a structured treatment plan for this oncology patient with NCI PDQ-grounded regimen choice, pre-treatment verification, toxicity monitoring, and supportive care. Do not generate executable orders. | Cancer: Cholangiocarcinoma | Stage: III | Intent: Adjuvant
Patient: 65y Female, 86.6 kg, BSA ~ 3.82 m^2
Performance status: ECOG 1 | Comorbidities: None documented
Labs: Hb 13.7, WBC 7.9, Plt 363, Cr 0.86, Bili 1.39, AST 225, ALT 193, Albumin 4
Biomarkers: medstack_synthetic_in_onco|biomarkers:subtype=Perihilar (Klatsk... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Treatment Plan — Cholangiocarcinoma (Adjuvant intent)**
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Guideline alignment
This line of reasoning aligns with the a... | medreason | oncology | treatment_plan | medstack_synthetic_in_onco | ONCO-IN-007578 |
You are MedStackAI Cardiac Assistant, a specialized cardiac DECISION-SUPPORT AI trained on de-identified Andhra Pradesh cardiac patient data, peer-reviewed cardiology guidelines (ACC/AHA, ESC), and evidence-based emergency cardiac care. You provide structured cardiac assessments to ASSIST a licensed clinician — you do ... | Summarize the hospital course and discharge plan for this cardiac patient. | Patient PAT-AP-000001: 37y Female
Admission diagnosis: Normal Sinus Rhythm
Procedure: None
Affected vessels: None
LVEF: 45%
Length of stay: 14 days
Outcome: Transferred to Higher Center
Medications administered: Nitroglycerin;Furosemide | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Framing the question
This case asks me to summarize the hospital course and discharge plan for this cardiac patient. I will reason from the presented case ... | medreason | cardiology | discharge_summary | medstack_synthetic_ap_cardiac | PAT-AP-000001 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Write a daily pediatric progress note in SOAP format with growth-chart anchoring, age-banded vital interpretation, response/AE assessment, and a family-centered plan. Cite NICHD and CDC for monitoring and discharge criteria. Do not reproduce AAP, IAP, or Nelson text. | Patient PEDS-IN-000001: 12d Male | Neonate (0-28 d) | 1.61 kg
Disease: Hypoxic-Ischemic Encephalopathy | Severity: APGAR 1-min: 0-3 / 5-min: 0-3 — severe HIE (Sarnat III) | Intent: Palliative / Supportive
Current regimen: Therapeutic hypothermia (33.5°C × 72h) within 6 hours of birth for ≥36-week neonates meeting crite... | <think>
### Framing the question
This case asks me to write a daily pediatric progress note in SOAP format with growth-chart anchoring, age-banded vital interpretation, response/AE assessment, and a family-centered plan. I will reason from the presented case data before committing to an answer.
### Key measured findin... | medreason | pediatrics | progress_note | medstack_synthetic_in_peds | PEDS-IN-000001 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Write a SOAP-format psychiatric progress note with measurement-based-care scale (PHQ-9 / GAD-7 / YMRS / PANSS / Y-BOCS / PCL-5 / AUDIT / C-SSRS / BFCRS / ISI / AIMS as disease-appropriate, referenced by name only), adverse-event review, suicide risk stratification, and evidence-based next-step plan per FDA labels / VA-... | Patient PSYCH-IN-000001: 54y Male
Disease: Bipolar I Disorder (Manic Episode) | Baseline severity: YMRS 14-25 (moderate mania) | Intent: Acute / Emergent
Current regimen: Acute mania (FDA-approved monotherapy options): lithium 600-1800 mg (target 0.8-1.2 mEq/L acute, 0.6-1.0 mEq/L maintenance), valproate / divalproex 7... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Psychiatric Progress Note (SOAP) — Bipolar I Disorder (Manic Episode)**
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessmen... | medreason | psychiatry | progress_note | medstack_synthetic_in_psych | PSYCH-IN-000001 |
You are MedStackAI AYUSH Assistant, a specialized AYUSH (Ayurveda + Yoga + Integrative Medicine) DECISION-SUPPORT AI trained on de-identified synthetic AYUSH patient data (India ICMR-AYUSH/CCRAS-weighted + Rest-of-World NCCIH-weighted) and license-clean public knowledge sources (CCRAS public bulletins, ICMR-AYUSH RCT r... | Generate a structured herb-drug interaction safety check for this patient. List each recommended Ayurvedic preparation's known interaction profile (encoded from CCRAS, NCCIH, EMEA HMPC, FDA, and Cochrane CM Field — referenced by name only). Cross-reference against the patient's current biomedical regimen and flag speci... | Patient AYUSH-INDIA-000001: 43 F | Psoriasis Vulgaris (Mild-Mod)
Recommended herbs: Mandukaparni (Centella asiatica); Haridra (Curcumin) (Curcuma longa); Neem (Azadirachta indica); Yashtimadhu (Licorice) (Glycyrrhiza glabra)
Per-herb encoded interactions: Mandukaparni: Hepatotoxicity reports — avoid in chronic liver di... | <think>
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Salient case facts
The case supplies these measured findings: 15 mg. These anchor the assessment.
### Restating the task
This case asks me to genera... | medreason | ayush_integrative | herb_drug_interaction_safety | medstack_synthetic_in_ayush | AYUSH-INDIA-000001 |
You are MedStackAI OncoBiomarker Decision-Support Assistant, a precision-oncology biomarker-to-therapy AI for eight tumor-system subspecialties (Thoracic, Breast, GI, GU, GYN, Melanoma, Heme, HNO-Thyroid). Trained on de-identified synthetic cases (India 70% / RoW 30%) and public knowledge anchors: AMP/ASCO/CAP 2017 (Li... | Assess whether this patient's biomarker has a current FDA tumor-agnostic indication, map to ESMO ESCAT tiers, and produce a tumor-agnostic vs tumor-specific decision-tree synthesis. | Case ONCOBM-IN-000001: 51 M | NSCLC adenocarcinoma (AJCC 8th ed Stage IV)
Biomarker: KRAS G12C | VAF 31% tissue; ctDNA VAF 3.8%
Subspecialty: thoracic | Concern: new diagnosis biopsy report under MTB review
Site: CMC Vellore Cancer Centre (india) | Setting: NCG India network comprehensive cancer centre with molecular t... | <think>
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Case Snapshot:**
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards... | medreason | oncobiomarker | tumor_agnostic_indication_check | medstack_synthetic_in_oncobiomarker | ONCOBM-IN-000001 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | For this radiology case, provide a differential diagnosis tied to the structured report findings, list common confounders or mimics to consider, and propose the recommended next-step workup (imaging / pathology / labs / nuc-med / genetics) with reference to the appropriate framework (ACR Appropriateness Criteria / WHO ... | Case MS-DX-INDIA-000000: 87 F | indication: oncologic staging
Subspecialty bucket: radiology
Site: NIMHANS Bengaluru (india) | Setting: NABH-accredited tertiary hospital nuclear medicine | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Framing the question
This case asks me to for t... | medreason | diagnostics_text | differential_with_recommended_workup | medstack_synthetic_in_diagnostics | MS-DX-INDIA-000000 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Provide renal + hepatic dose modification for this Indian patient. State both renal (KDIGO + FDA label) and hepatic (Child-Pugh + FDA label) adjustments, the combined-impairment override rule, monitoring cadence, and geriatric overlay (Beers 2023 / STOPP/START v3) if age ≥ 65. Use the patient's actual CrCl and Child-Pu... | Patient PHARM-INDIA-000001: 83 M, 109 kg, CrCl 63, Child-Pugh C
Regimen: enalapril (ACE inhibitor); amitriptyline (TCA); tramadol (opioid agonist + SNRI); enoxaparin (rule-grounded adjunct)
Renal-relevant drug: enoxaparin
Hepatic-relevant drug: tramadol | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Framing the question
This case asks me to provide renal + hepatic dose modification for this Indian patient. I will reason from the presented case data before committing to an answer.... | medreason | pharmacy_drugdev | renal_hepatic_dose_modification | medstack_synthetic_in_pharmacy | PHARM-INDIA-000001 |
You are MedStackAI PayerOps Assistant, a specialized end-to-end revenue cycle management decision-support AI covering the full claim lifecycle for US + India payer ecosystems. Trained on de-identified synthetic RCM cases (US 60% / India 40% weighted) across 11 subspecialties (inpatient RCM, outpatient hospital, pro-fee... | Build the complete pre-service workflow for this case: (1) eligibility verification via X12 270/271; (2) prior authorization via X12 278 with status + medical-necessity basis; (3) medical-necessity letter shape; (4) No Surprises Act Good Faith Estimate determination; (5) concurrent utilization review readiness; (6) pat... | Case PAY-US-0003361: 76 M
Subspecialty: ed billing; Setting: ed; Facility: community hospital (250 beds, non-teaching)
Payer: Aetna commercial HMO (commercial_us)
Primary Dx: S52.501A Unspecified fracture of lower end of right radius, initial encounter closed
Secondary Dx: W19.XXXA|Unspecified fall initial encounter
CP... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: ⚠️ RCM DECISION SUPPORT — not a substitute for a certified coder (CCS/CCS-P/CPC), CDI specialist (CCDS), compliance officer, or RCM director sign-off; verify every code/rate/policy against current…
### Clinical interpretation
I... | medreason | payerops | pre_service_eligibility_and_authorization | medstack_synthetic_us_payerops | PAY-US-0003361 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Produce the subspecialty-specific management plan for this case. Cover non-pharmacologic + pharmacologic + procedural / surgical steps as applicable, with named drug + dose + duration (public formulary only), and explicit guideline anchor. End with the escalation pathway if findings worsen. | case_id: OBGYN-INDIA-000190
region: india
subspecialty: reproductive_endocrinology_infertility
facility: PGIMER Chandigarh OB-GYN (tertiary teaching)
patient: 25yo female, parity G3P0A0L0, BMI 21.4
GA: N/A (non-pregnant)
presenting_complaint: Diminished ovarian reserve (AMH 0.4 ng/mL) seeking IVF counseling
primary_dx:... | <think>
### Pulling the relevant data
The case supplies these measured findings: 0.4 ng/mL. These anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Management plan
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented ... | medreason | obgyn | management_plan | medstack_obgyn_v1 | OBGYN-INDIA-000190 |
You are MedStackAI PublicHealth Assistant, a specialized public-health + epidemiology + program-implementation decision-support AI covering the surveillance + response + program-implementation + policy + risk-communication surface for India + WHO global + US/EU domains. Trained on de-identified synthetic public-health ... | Produce the subspecialty-specific response plan or program implementation strategy. Cover activation, intersectoral, IEC/RCCE, resource + logistics (HRH + supplies + cold-chain + drugs), and the explicit named guideline anchor. End with the escalation pathway. | case_id: PH-INDIA-008809
region: india
subspecialty: ntep_tb
setting: PHC catchment in Bihar (block-level, ~30k pop)
scenario: DR-TB management capacity review against MDR-TB notifications
population: 15-49; scale: ~12 MDR this quarter, PMDT capacity adequate
indicator: MDR-TB notification + initiation on BPaL/BPaLM re... | <think>
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Clinical interpretation
Interpreting these findings in th... | medreason | publichealth | response_or_program_plan | medstack_publichealth_v1 | PH-INDIA-008809 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Identify the relevant HEDIS / CMS Stars / Million Hearts / MIPS / HRRP quality measures + risk-adjustment HCC capture opportunities for this patient. List care-gap closure actions with denominator/numerator integrity in mind, SDoH Z-code capture, and India quality-measure analogs (NP-NCD / IHCI / NABH) where applicable... | patient_id: CC-INDIA-008926
region: india; setting: PGIMER Chandigarh CKD clinic
demographics: age 80 F (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 24.5
disability status: none reported
subspecialty: hf
scenario: HFrEF (EF 32%) on partial GDMT — quadruple therapy + SGLT2i ... | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Key measured findings
The case supplies these measured findings: 25mg. These anchor the assessment.
### Weighing alternatives
Alternative explanations were considered, but they fit t... | medreason | chroniccare | care_gap_or_quality_measure | medstack_chroniccare_v1 | CC-INDIA-008926 |
You are MedStackAI PatentDraft Assistant, a specialized patent + IP decision-support AI covering pharma composition + pharma method-of-use + medtech device + diagnostic method + digital health subject matter across US (USPTO) + EPO + India (IPO) jurisdictions. Trained on de-identified synthetic patent cases (US 50% / I... | Outline the prosecution strategy + Patent-Term-Extension (PTE) / SPC / Hatch-Waxman / IRA / Bolar / IPR / PGR / EPO opposition / India pre-grant + post-grant opposition for this case. Include continuation + PCT + PPH options and ANDA Para IV considerations where applicable. | case_id: PD-US-007435
jurisdiction: us; filing_status: US AIA-IPR patent-owner-side analysis
subspecialty: digital_health
invention: Smartphone-app-delivered closed-loop AI titration of basal insulin in T2DM with safety guardrails + EHR integration via SMART-on-FHIR
technical_field: Digital health / SaMD / closed-loop ... | <think>
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Framing the question
This case asks me t... | medreason | patentdraft | prosecution_strategy_and_term_extension | medstack_patentdraft_v1 | PD-US-007435 |
You are MedStackAI Neuro Decision-Support Assistant, a specialized neurology + addiction-medicine + pain-medicine decision-support AI for EIGHT subspecialties (Stroke, Epilepsy, Multiple Sclerosis & Demyelinating Disease, Movement Disorders, Headache, Neuromuscular Disease, Addiction Medicine, Pain Medicine). Trained o... | For this neuromuscular case, generate a long-term monitoring + secondary-prevention plan. State the framework principle, then provide patient-specific monitoring + prevention items. Add the RoW EHR registries / CMS quality / specialty pharmacy / patient portal monitoring overlay. | Case MS-NEURO-ROW-004731: 23 F | concern: acute neurological event
Subspecialty bucket: neuromuscular
Site: Mass General Boston Neuroscience (row) | Setting: headache specialty clinic (UCNS-certified) | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Bringing it together
T... | medreason | neuro | long_term_monitoring_and_secondary_prevention | medstack_synthetic_rw_neuro | MS-NEURO-ROW-004731 |
You are MedStackAI Surgical Decision-Support Assistant, a specialized perioperative + intraoperative + postoperative + surgical-oncology decision-support AI trained on de-identified synthetic surgical patients (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (ACS NSQIP Surgical Risk C... | Manage the post-operative course of this RoW patient after damage-control laparotomy for blunt abdominal trauma. State whether a complication has occurred, assign the Clavien-Dindo grade, provide complication-specific management, comment on ERAS Society protocol applicability, list discharge readiness criteria, and inc... | Patient MS-SURG-RW-005205: 20 F, ASA II
Procedure: damage-control laparotomy for blunt abdominal trauma (open)
Complication: AKI | Clavien-Dindo: IIIa
ERAS: NO — no published ERAS Society protocol for this procedure subspecialty | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Salient case facts
The dossier above supplies the qualitative findings that anchor the assessment.
### What is being asked
This case asks me to manage the post-operative course of th... | medreason | surgical | postop_complication_management | medstack_synthetic_rw_surgical | MS-SURG-RW-005205 |
You are MedStackAI Hospital-Based Specialty Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for the five hospital-based subspecialties (Emergency Medicine, Anesthesiology, Hospital Medicine [Hospitalist], Critical Care, and Palliative / Hospice Care). Trained on de-identified synthe... | For this critical care patient, provide a structured family + team communication plan using the VALUE and NURSE frameworks. State the structured family-meeting agenda (8 steps), the patient-specific scenarios to anticipate, the intra-team communication discipline (multidisciplinary rounds / closed-loop / speak-up cultu... | Patient MS-HOSP-ROW-004089: 88 F, ASA I
Subspecialty: critical care
Comorbidities: asthma; atrial fibrillation; metastatic cancer; prior stroke
Active meds: OTC analgesic prn; apixaban 5 mg BID; individualized chemotherapy regimen (per oncologist); OTC analgesic prn | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Salient case facts
The case supplies these measured findings: 5 mg. These anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Family + Tea... | medreason | hospital_based | family_team_communication | medstack_synthetic_rw_hospital | MS-HOSP-ROW-004089 |
You are MedStackAI Other-Clinical Decision-Support Assistant, a specialized outpatient + allied-health decision-support AI for SIX subspecialties (Dermatology, Physical Medicine & Rehabilitation, Sports Medicine, Nutrition, Reproductive Medicine, Occupational Medicine). Trained on de-identified synthetic outpatient cas... | For this dermatology case, generate a risk-stratification + preventive-screening plan. State the named framework references (USPSTF / ICMR + NHM / subspecialty society). Provide patient-specific screening tied to the subspecialty + diagnosis. Add the India NHM / CBAC / HWC / tier-2 access screening overlay. | Case MS-OC-INDIA-000000: 65 F | concern: symptom management
Subspecialty bucket: dermatology
Site: Madras Medical College Chennai (india) | Setting: tertiary government teaching hospital outpatient | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Salient case facts
The dossier above supplies the qualitative findings that anchor the assessment.
### Standards of care
This line of reasoning aligns with th... | medreason | other_clinical | risk_stratification_and_screening | medstack_synthetic_in_other_clinical | MS-OC-INDIA-000000 |
You are MedStackAI Bedside-Specialties Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for SEVEN bedside specialties (Gastroenterology, Pulmonology, Nephrology, Rheumatology, Hematology, Infectious Disease, Emergency Medicine). Trained on de-identified synthetic inpatient/acute case... | Risk-stratify this pulmonology case (active pulmonary tuberculosis (smear/CBNAAT positive)). State the SEVERITY TIER, the STRATIFICATION BASIS using the named validated score, explicit ESCALATION THRESHOLDS to a higher level of care, and SAFETY CHECKS — anchored to India NTEP 2024 / WHO TB (named). | Case BS-INDIA-343263: 41 F | pulmonology | severity: urgent
Presenting picture: cough >2 weeks, evening fever, night sweats, weight loss, hemoptysis; upper-lobe infiltrate on CXR; high-burden setting
Site: Apollo Chennai (india) | Setting: tertiary government teaching hospital ward | <think>
### Restating the task
This case asks me to risk-stratify this pulmonology case (active pulmonary tuberculosis (smear/CBNAAT positive)). I will reason from the presented case data before committing to an answer.
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and acc... | medreason | bedside_specialties | acute_risk_stratification | medstack_synthetic_in_bedside | BS-INDIA-343263 |
You are MedStackAI Citation-Grounded Evidence-Based-Medicine Decision-Support Assistant. You answer clinical questions in an evidence-based way: every key claim carries an inline numeric citation like [1], and you end the clinical content with a numbered References list that maps each marker to a named landmark trial o... | Answer this clinical question with every key claim carrying an inline citation and a numbered References list: "Does low-dose aspirin prevent pre-eclampsia in high-risk pregnancies?". Include the main caveat. Never fabricate a reference. | EBM case EBM-IN-000001 | area: obstetrics | topic: low-dose aspirin for pre-eclampsia prevention
Clinical question: Does low-dose aspirin prevent pre-eclampsia in high-risk pregnancies?
Population: pregnant women at high risk of pre-eclampsia
Context: A clinician at a tertiary teaching hospital in India is reviewing th... | <think>
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
... | medreason | citation_ebm | citation_grounded_answer | medstack_synthetic_in_citation_ebm | EBM-IN-000001 |
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Build a comprehensive preventive cancer care plan for this India oncology patient covering survivorship surveillance, genetic counseling, chemoprevention, vaccination, and second-primary screening. Cite NCI PDQ Screening & Prevention, NCI PDQ Survivorship, and ICMR India screening guidance. Do not reproduce NCCN, ESMO,... | Patient ONCO-IN-002197: 39y Female | Location: Telangana (India / South)
Active cancer: Oral Cavity Cancer (SCC) | Stage: III | Intent: Adjuvant
Comorbidities: CKD stage 3
BMI: 31.9
Performance status: ECOG 4 | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Putting the picture together
Inter... | medreason | oncology | preventive_care | medstack_synthetic_in_onco | ONCO-IN-002197 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Build a comprehensive preventive pediatric care plan for this India patient covering immunizations (UIP + RBSK + CDC catch-up), age-banded growth and developmental monitoring on CDC/WHO charts, micronutrient supplementation per ICMR (Vitamin A, IFA, deworming), USPSTF + RBSK screening, and CDC age-appropriate injury pr... | Patient PEDS-IN-000001: 12d Male | Neonate (0-28 d)
Weight 1.61 kg | Height 47 cm | BMI 7.3
Active concern: Hypoxic-Ischemic Encephalopathy (APGAR 1-min: 0-3 / 5-min: 0-3 — severe HIE (Sarnat III))
Comorbidities: None documented
Location: Rajasthan (India / North) | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### What is being asked
This case asks me to build a comprehensive preventive pediatric care plan for this India patient covering immunizations (UIP + RBSK + CDC catch-up), age-banded gro... | medreason | pediatrics | preventive_care | medstack_synthetic_in_peds | PEDS-IN-000001 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Generate a comprehensive preventive screening + safety plan for this adult psychiatry patient including disease-specific relapse prevention, USPSTF universal mental health + general adult screening, FDA-labeled antipsychotic / mood stabilizer metabolic + movement surveillance, Stanley-Brown suicide safety planning, and... | Patient PSYCH-IN-000001: 54y Male | Region: India / Northeast
Disease: Bipolar I Disorder (Manic Episode) | Severity: YMRS 14-25 (moderate mania)
Comorbidities: None documented
Functional baseline: GAF 51-60 (moderate symptoms; moderate difficulty)
Biomarkers: medstack_synthetic_in_psych|biomarkers:cyp2d6_phenotype=Nor... | <think>
### Restating the task
This case asks me to generate a comprehensive preventive screening + safety plan for this adult psychiatry patient including disease-specific relapse prevention, USPSTF universal mental health + general adult screening, FDA-labeled antipsychotic / mood stabilizer metabolic + movement surv... | medreason | psychiatry | preventive_screening | medstack_synthetic_in_psych | PSYCH-IN-000001 |
You are MedStackAI AYUSH Assistant, a specialized AYUSH (Ayurveda + Yoga + Integrative Medicine) DECISION-SUPPORT AI trained on de-identified synthetic AYUSH patient data (India ICMR-AYUSH/CCRAS-weighted + Rest-of-World NCCIH-weighted) and license-clean public knowledge sources (CCRAS public bulletins, ICMR-AYUSH RCT r... | Grade the evidence behind the proposed AYUSH intervention for this patient using the 5-tier EBM-AYUSH framework (Tier-1 Cochrane SR → Tier-5 classical text only). State the assigned tier, rationale, limitations, and a tier-appropriate clinical decision (offer as primary / adjunctive only / low-risk adjunctive only / do... | Patient AYUSH-INDIA-000001: 43 F | Psoriasis Vulgaris (Mild-Mod) (severity: PASI 3-10 — moderate)
Proposed intervention class: Integrative (AYUSH adjunct to allopathy)
Specific preparations: Mandukaparni (Centella asiatica); Haridra (Curcumin) (Curcuma longa); Neem (Azadirachta indica); Yashtimadhu (Licorice) (Glycyrrh... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: AYUSH Evidence Grading — Integrative (AYUSH adjunct to allopathy) for Psoriasis Vulgaris (Mild-Mod)**
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data le... | medreason | ayush_integrative | ayush_ebm_evidence_grading | medstack_synthetic_in_ayush | AYUSH-INDIA-000001 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | Generate a nuclear medicine report for this bone scan (Tc-99m MDP) (indication: staging or restaging bone metastases (prostate, breast, lung)). Include TRACER + TECHNIQUE per SNMMI procedure standard, SCORING SYSTEM (named: qualitative: no metastatic disease / indeterminate / probable / definite metastatic disease; PCW... | Case MS-DX-ROW-001947: 85 F | indication: screening / surveillance
Subspecialty bucket: nuclear medicine
Site: Royal Marsden London (row) | Setting: academic medical center radiology | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Clinical interpretation
Interpreting these findings in th... | medreason | diagnostics_text | structured_report_findings_impression | medstack_synthetic_rw_diagnostics | MS-DX-ROW-001947 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Conduct a full-regimen safety review for this RoW patient. Identify the primary safety flag and apply cross-cutting checks (ACB sum, FDA opioid+benzo black-box, serotonin syndrome red flags, QT thresholds, Beers 2023 + STOPP/START v3 if ≥ 65, renal + hepatic clearance flags, polypharmacy ≥ 5 drugs review), and provide ... | Patient PHARM-ROW-003708: 85 F, 92 kg, CrCl 70, Child-Pugh None
Regimen: tamoxifen (SERM); gabapentin (gabapentinoid); oxycodone (opioid agonist); fluoxetine (SSRI); atorvastatin (HMG-CoA reductase inhibitor)
Primary safety flag: beers
Detail: No high-risk stack detected; routine Beers 2023 / STOPP/START v3 review at e... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Full-Regimen Safety Review — BEERS**
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Standards of care... | medreason | pharmacy_drugdev | regimen_safety_review | medstack_synthetic_rw_pharmacy | PHARM-ROW-003708 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Produce the counseling + shared-decision-making summary suitable for the patient and (if applicable) birth-companion / spouse / family / adolescent legal guardian. Use clear, non-judgmental language. End with India RMNCH+A program-linkage info when the case is in India; otherwise mark non-applicable. | case_id: OBGYN-INDIA-004405
region: india
subspecialty: intrapartum_labor_delivery
facility: NHM Primary Health Centre with 24x7 delivery (PHC)
patient: 27yo female, parity G4P1A1L0, BMI 36.8
GA: 39 weeks
presenting_complaint: Postpartum hemorrhage (>1000 mL EBL post-vaginal birth)
primary_dx: O72.1 — Other immediate p... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Counseling message
### What is being asked
This case asks me to produce the counseling + shared-decision-making summary suitable for the patient and (if applicable) birth-companion / spouse / family / adolescent legal guardian.... | medreason | obgyn | counseling_shared_decision | medstack_obgyn_v1 | OBGYN-INDIA-004405 |
You are MedStackAI PublicHealth Assistant, a specialized public-health + epidemiology + program-implementation decision-support AI covering the surveillance + response + program-implementation + policy + risk-communication surface for India + WHO global + US/EU domains. Trained on de-identified synthetic public-health ... | Produce the subspecialty-specific response plan or program implementation strategy. Cover activation, intersectoral, IEC/RCCE, resource + logistics (HRH + supplies + cold-chain + drugs), and the explicit named guideline anchor. End with the escalation pathway. | case_id: PH-ROW-005773
region: row
subspecialty: nvbdcp_vector
setting: BMGF country office (LMIC implementation)
scenario: Malaria transmission review in a tribal district (API trigger)
population: all-ages; scale: resurgence vs baseline API 0.6
indicator: API (annual parasite incidence per 1000) + Pf share = API 2.4;... | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### What is being asked
This case ... | medreason | publichealth | response_or_program_plan | medstack_publichealth_v1 | PH-ROW-005773 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Produce the subspecialty-specific management plan for the chronic-care continuum. Cover pharmacotherapy + lifestyle + monitoring + comorbidity-management + India program linkage if applicable. End with the named guideline anchor. | patient_id: CC-INDIA-006838
region: india; setting: Fortis Mumbai HF programme
demographics: age 50 F (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 27.1
disability status: none reported
subspecialty: dm
scenario: T2DM with HbA1c 9.4% on dual therapy; ASCVD high-risk; SGLT2i ... | <think>
### What is being asked
This case asks me to produce the subspecialty-specific management plan for the chronic-care continuum. I will reason from the presented case data before committing to an answer.
### Considering other explanations
Alternative explanations were considered, but they fit the presented data ... | medreason | chroniccare | management_plan_chronic_continuum | medstack_chroniccare_v1 | CC-INDIA-006838 |
You are MedStackAI PatentDraft Assistant, a specialized patent + IP decision-support AI covering pharma composition + pharma method-of-use + medtech device + diagnostic method + digital health subject matter across US (USPTO) + EPO + India (IPO) jurisdictions. Trained on de-identified synthetic patent cases (US 50% / I... | Outline the prosecution strategy + Patent-Term-Extension (PTE) / SPC / Hatch-Waxman / IRA / Bolar / IPR / PGR / EPO opposition / India pre-grant + post-grant opposition for this case. Include continuation + PCT + PPH options and ANDA Para IV considerations where applicable. | case_id: PD-EPO-000001
jurisdiction: epo; filing_status: EPO appeal at Boards of Appeal
subspecialty: medtech_device
invention: Active-fixation transcatheter aortic valve replacement (TAVR) delivery catheter with proximal radiopaque marker band + capsule recapture mechanism for repositioning
technical_field: Cardiovasc... | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
##... | medreason | patentdraft | prosecution_strategy_and_term_extension | medstack_patentdraft_v1 | PD-EPO-000001 |
You are MedStackAI Neuro Decision-Support Assistant, a specialized neurology + addiction-medicine + pain-medicine decision-support AI for EIGHT subspecialties (Stroke, Epilepsy, Multiple Sclerosis & Demyelinating Disease, Movement Disorders, Headache, Neuromuscular Disease, Addiction Medicine, Pain Medicine). Trained o... | Generate the stroke primary management plan for this case (transient ischemic attack (high-risk by ABCD2)). Include PRIMARY DIAGNOSIS, SEVERITY (NIHSS / mRS / scoring), IMAGING (CT / CTA / MRI / perfusion), REPERFUSION / SURGICAL ELIGIBILITY (AHA/ASA + DAWN/DEFUSE-3 + ISAT framework), ACUTE TREATMENT PLAN, SECONDARY PR... | Case MS-NEURO-ROW-003808: 67 M | concern: medication titration + safety
Subspecialty bucket: stroke
Site: Johns Hopkins Neurology (row) | Setting: multidisciplinary chronic-pain center (board-certified pain medicine) | <think>
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Arriving at the recommendation
Taken toget... | medreason | neuro | subspecialty_primary_management | medstack_synthetic_rw_neuro | MS-NEURO-ROW-003808 |
You are MedStackAI Surgical Decision-Support Assistant, a specialized perioperative + intraoperative + postoperative + surgical-oncology decision-support AI trained on de-identified synthetic surgical patients (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (ACS NSQIP Surgical Risk C... | Perform a structured pre-operative assessment and risk stratification for this Indian patient scheduled for phacoemulsification + IOL implant for senile cataract. State the RCRI score with predicted cardiac event rate and contributing components, the Caprini VTE score with prophylaxis recipe, the ACS NSQIP morbidity / ... | Patient MS-SURG-IN-000001: 47 M, 58 kg, BMI 20.3, ASA II
Procedure: phacoemulsification + IOL implant for senile cataract (ophthalmology, urgent, endoscopic)
Comorbidities: rheumatoid arthritis on biologics
Active meds: levothyroxine 75 mcg OD; aspirin 75 mg OD; gabapentin 300 mg TDS; metoprolol 50 mg BD; prednisolone ... | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Framing the question
This case... | medreason | surgical | preop_assessment_riskstratification | medstack_synthetic_in_surgical | MS-SURG-IN-000001 |
You are MedStackAI Hospital-Based Specialty Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for the five hospital-based subspecialties (Emergency Medicine, Anesthesiology, Hospital Medicine [Hospitalist], Critical Care, and Palliative / Hospice Care). Trained on de-identified synthe... | For this critical care patient, provide a structured family + team communication plan using the VALUE and NURSE frameworks. State the structured family-meeting agenda (8 steps), the patient-specific scenarios to anticipate, the intra-team communication discipline (multidisciplinary rounds / closed-loop / speak-up cultu... | Patient MS-HOSP-INDIA-000000: 53 F, ASA V
Subspecialty: critical care
Comorbidities: hypertension
Active meds: amlodipine 5 mg OD | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Bringing it together
Taken together, this supports the conclusion that follows: Family + Team Communication — critical care**
### Interpreting the finding... | medreason | hospital_based | family_team_communication | medstack_synthetic_in_hospital | MS-HOSP-INDIA-000000 |
You are MedStackAI Other-Clinical Decision-Support Assistant, a specialized outpatient + allied-health decision-support AI for SIX subspecialties (Dermatology, Physical Medicine & Rehabilitation, Sports Medicine, Nutrition, Reproductive Medicine, Occupational Medicine). Trained on de-identified synthetic outpatient cas... | Generate the reproductive medicine primary management plan for this case (recurrent pregnancy loss (3 consecutive < 10 weeks)). Include PRIMARY DIAGNOSIS, WORKUP (ASRM / ACOG / WHO MEC framework, named), TREATMENT PLAN, COUNSELING (shared decision-making). Add the RoW SART / state mandates / ASRM ethics overlay. | Case MS-OC-ROW-003786: 69 M | concern: work or fitness clearance
Subspecialty bucket: reproductive medicine
Site: Stanford Health (row) | Setting: sports medicine + orthopedic surgery group | <think>
### What is being asked
This case asks me to generate the reproductive medicine primary management plan for this case (recurrent pregnancy loss (3 consecutive < 10 weeks)). I will reason from the presented case data before committing to an answer.
### Bringing it together
Taken together, this supports the conc... | medreason | other_clinical | subspecialty_primary_management | medstack_synthetic_rw_other_clinical | MS-OC-ROW-003786 |
You are MedStackAI Citation-Grounded Evidence-Based-Medicine Decision-Support Assistant. You answer clinical questions in an evidence-based way: every key claim carries an inline numeric citation like [1], and you end the clinical content with a numbered References list that maps each marker to a named landmark trial o... | State the current guideline-backed recommendation on "anticoagulation choice and duration in venous thromboembolism", give its grade, and name the governing guideline. Cite inline with a numbered References list; never fabricate a reference. | EBM case EBM-IN-006672 | area: hematology | topic: anticoagulation choice and duration in venous thromboembolism
Clinical question: Which anticoagulant and what duration are recommended for venous thromboembolism?
Population: adults with acute VTE without contraindication to anticoagulation
Context: A clinician at a pr... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Guideline-backed recommendation — anticoagulation choice and duration in venous thromboembolism**
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Pu... | medreason | citation_ebm | guideline_recommendation | medstack_synthetic_in_citation_ebm | EBM-IN-006672 |
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Generate a structured treatment plan for this oncology patient with NCI PDQ-grounded regimen choice, pre-treatment verification, toxicity monitoring, and supportive care. Do not generate executable orders. | Cancer: Nasopharynx Cancer | Stage: I | Intent: Curative
Patient: 58y Male, 55.6 kg, BSA ~ 2.80 m^2
Performance status: ECOG 0 | Comorbidities: CKD stage 3
Labs: Hb 9.2, WBC 2.9, Plt 58, Cr 1.42, Bili 0.88, AST 149, ALT 189, Albumin 3.9
Biomarkers: medstack_synthetic_rw_onco|biomarkers:molecular_workup=Standard histopa... | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Bringing it together
Taken toget... | medreason | oncology | treatment_plan | medstack_synthetic_rw_onco | ONCO-RW-001432 |
You are MedStackAI Cardiac Assistant, a specialized cardiac DECISION-SUPPORT AI trained on de-identified Andhra Pradesh cardiac patient data, peer-reviewed cardiology guidelines (ACC/AHA, ESC), and evidence-based emergency cardiac care. You provide structured cardiac assessments to ASSIST a licensed clinician — you do ... | Interpret this ECG and provide clinical correlation. | Patient: 55y Male
Presenting complaint: Fatigue
HR 75, BP 140/74
Troponin I: 0.032 ng/mL
ST elevation: -0.2mm | <think>
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### What is being asked
This case asks me to interpret this ECG and provide clinical correlation. I will reason from the presented case data before ... | medreason | cardiology | ecg_interpretation | medstack_synthetic_ap_cardiac | PAT-AP-000002 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Generate a pediatric pharmacogenomic assessment grounded in CPIC guidelines and FDA pediatric labels. Apply PGx-INDEPENDENT pediatric Boxed Warnings first (codeine/tramadol <12 y, aspirin/Reye), then phenotype-specific guidance for CYP2D6, CYP2C19, TPMT/NUDT15, HLA-B*15:02, and G6PD. Cite CPIC and FDA labels explicitly... | Patient PEDS-IN-000001: 12d Male | Neonate (0-28 d) | 1.61 kg
Disease context: Hypoxic-Ischemic Encephalopathy
Comorbidities: None documented
PGx panel + disease biomarkers: medstack_synthetic_in_peds|biomarkers:HLA-B*15:02=NEGATIVE; G6PD=NORMAL; CYP2D6=NORMAL METABOLIZER (FDA boxed warning: codeine and tramadol contra... | <think>
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Standards of care
This line of reasoning ali... | medreason | pediatrics | pharmacogenomics | medstack_synthetic_in_peds | PEDS-IN-000001 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Match this adult psychiatry patient's pharmacogenomic profile against CPIC + FDA-approved psychotropic PGx biomarkers and provide actionable psychotropic dosing / selection guidance, or explicit "no actionable flag" stub. Cite CPIC + FDA labels + VA-DoD CPGs + LactMed explicitly. | Patient PSYCH-IN-000001: 54y Male | Region: India / Northeast
Disease: Bipolar I Disorder (Manic Episode) | Severity: YMRS 14-25 (moderate mania)
Comorbidities: None documented
Biomarkers: medstack_synthetic_in_psych|biomarkers:cyp2d6_phenotype=Normal metabolizer (NM); cyp2c19_phenotype=Normal metabolizer (NM); hla_b15... | <think>
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Arriving at the recommenda... | medreason | psychiatry | pharmacogenomic_match | medstack_synthetic_in_psych | PSYCH-IN-000001 |
You are MedStackAI AYUSH Assistant, a specialized AYUSH (Ayurveda + Yoga + Integrative Medicine) DECISION-SUPPORT AI trained on de-identified synthetic AYUSH patient data (India ICMR-AYUSH/CCRAS-weighted + Rest-of-World NCCIH-weighted) and license-clean public knowledge sources (CCRAS public bulletins, ICMR-AYUSH RCT r... | Perform a structured prakriti / vikriti assessment for this Indian patient using the public-domain dosha framework (Vata / Pitta / Kapha) referenced by name only — NO Charaka / Sushruta / Ashtanga Hridaya / Bhavaprakasha text reproduction. State prakriti, current vikriti, sama vs nirama state, and biomedical correlatio... | Patient AYUSH-INDIA-000002: 37 F | Gujarat (india)
Setting: Integrative Oncology Outpatient Unit
Biomedical condition: Perimenopausal Syndrome | Severity: Mild — outpatient AYUSH amenable, biomedical baseline obtained
Classical correlate: Rajonivritti | System domain: gyn
Prakriti (constitutional baseline): Vata-Kapha
... | <think>
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Arriving at the recommendation
Taken together, ... | medreason | ayush_integrative | prakriti_assessment_classical | medstack_synthetic_in_ayush | AYUSH-INDIA-000002 |
You are MedStackAI OncoBiomarker Decision-Support Assistant, a precision-oncology biomarker-to-therapy AI for eight tumor-system subspecialties (Thoracic, Breast, GI, GU, GYN, Melanoma, Heme, HNO-Thyroid). Trained on de-identified synthetic cases (India 70% / RoW 30%) and public knowledge anchors: AMP/ASCO/CAP 2017 (Li... | Give the variant-interpretation + clinical-significance read-out: interpret the variant, its AMP/ASCO/CAP + ESCAT classification, companion-diagnostic confirmation, and what it does/does not establish for therapy. | Case ONCOBM-IN-005614: 58 F | cutaneous melanoma (AJCC 8th ed Stage IV)
Biomarker: PD-L1 + TMB-H + LDH-normal | PD-L1 IHC variable; TMB ≥ 10 mut/Mb (FoundationOne CDx, FDA-CDx for tumor-agnostic pembrolizumab)
Subspecialty: melanoma | Concern: consideration for clinical trial enrollment after standard of care exhausted... | <think>
### Bringing it together
Taken together, this supports the conclusion that follows: Case Snapshot:**
### Salient case facts
The dossier above supplies the qualitative findings that anchor the assessment.
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible ... | medreason | oncobiomarker | biomarker_interpretation_lens | medstack_synthetic_in_oncobiomarker | ONCOBM-IN-005614 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | Generate a structured radiology report for this pelvic US or MR of the ovary/adnexa (indication: adnexal lesion characterization). Include TECHNIQUE, COMPARISON, FINDINGS, IMPRESSION (with explicit numbered impression line + recommendation tied to the assigned O-RADS category), and the ACR Appropriateness Criteria chec... | Case MS-DX-INDIA-000001: 80 M | indication: symptomatic workup
Subspecialty bucket: radiology
Site: Manipal Bengaluru (india) | Setting: NABH-accredited tertiary hospital nuclear medicine | <think>
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Bringing it together
Taken together, this supports the conclusion that follows: Structured Radiology Report — pelvic US or MR of the ovary/adnexa (adnexal lesion characterization)**
### Ruling out... | medreason | diagnostics_text | structured_report_findings_impression | medstack_synthetic_in_diagnostics | MS-DX-INDIA-000001 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Provide a target-to-lead ADMET brief grounded in license-clean ChEMBL + PubChem context. Include indication area, illustrative lead SMILES + computed QED + Lipinski pass, ADMET concerns, the standard pre-IND in vitro screening cascade (solubility, permeability, metabolic stability, CYP inhibition / induction, PPB, hERG... | Target: NLRP3 (NLR family pyrin domain containing 3 inflammasome)
Indication area: Cardiovascular inflammation (post-MI), gout, autoinflammatory [cardio]
Lead SMILES: CC(C)c1cc(C(=O)NS(=O)(=O)c2ccccc2)c(O)cc1
QED: 0.67 | Lipinski pass: YES
ADMET concern: CYP3A4 metabolism risk with sulfonylurea-like core; DDI screen wi... | <think>
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Restating the task
This case asks me to provide a target-to-lead ADMET brief grounded in license-clean ChEMBL + PubChem context. I will reason from... | medreason | pharmacy_drugdev | target_to_lead_admet_brief | medstack_synthetic_in_pharmacy | PHARM-INDIA-000001 |
You are MedStackAI PayerOps Assistant, a specialized end-to-end revenue cycle management decision-support AI covering the full claim lifecycle for US + India payer ecosystems. Trained on de-identified synthetic RCM cases (US 60% / India 40% weighted) across 11 subspecialties (inpatient RCM, outpatient hospital, pro-fee... | Produce the prescriptive next-step / workqueue routing for this case: from the current claim state, give the single highest-value next action (with the dollar/deadline rationale), the owner, and the timeframe for this exact case. | Case PAY-INDIA-0006326: 37 F
Subspecialty: india govt payer; Setting: inpatient; Facility: AIIMS / PGIMER tertiary public teaching hospital
Payer: ESIC (Employees State Insurance Corporation) (esic)
Primary Dx: O80 Normal vaginal delivery — PMJAY / state scheme RSBY-equivalent
Secondary Dx: Z37.0|Single live birth; Z3A... | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Framing the question
This case asks me to produce the prescriptive next-step / workqueue routing for this case: from the current claim state, give the single highest-value next action... | medreason | payerops | next_best_action | medstack_synthetic_in_payerops | PAY-INDIA-0006326 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Give the population + program-linkage perspective for this encounter: describe how this case rolls up to the panel / program / registry denominator, the screening-coverage action it triggers, and the equity / access gap at population level. Cite the named program or guideline anchor. | case_id: OBGYN-INDIA-000001
region: india
subspecialty: reproductive_endocrinology_infertility
facility: JSSK + JSY-implementing government hospital
patient: 28yo female, parity G4P3A0L2, BMI 32.9
GA: N/A (non-pregnant)
presenting_complaint: Oncofertility — fertility preservation counseling before gonadotoxic chemother... | <think>
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
... | medreason | obgyn | population_health | medstack_obgyn_v1 | OBGYN-INDIA-000001 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Produce a plain-language patient education + shared-decision-making message for this patient at appropriate health-literacy level. Cover self-management, monitoring, medication adherence, warning signs requiring care escalation, and culturally-appropriate lifestyle counseling. | patient_id: CC-INDIA-007517
region: india; setting: PHC catchment Maharashtra
demographics: age 59 F (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 23.3
disability status: none reported
subspecialty: htn_cvd
scenario: Statin-eligible primary prevention with borderline LDL on ... | <think>
### Guideline alignment
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Patient education + shared decision
### Salient case facts
The case supplies these measured ... | medreason | chroniccare | patient_education_and_shared_decision | medstack_chroniccare_v1 | CC-INDIA-007517 |
You are MedStackAI Neuro Decision-Support Assistant, a specialized neurology + addiction-medicine + pain-medicine decision-support AI for EIGHT subspecialties (Stroke, Epilepsy, Multiple Sclerosis & Demyelinating Disease, Movement Disorders, Headache, Neuromuscular Disease, Addiction Medicine, Pain Medicine). Trained o... | Generate the stroke primary management plan for this case (transient ischemic attack (high-risk by ABCD2)). Include PRIMARY DIAGNOSIS, SEVERITY (NIHSS / mRS / scoring), IMAGING (CT / CTA / MRI / perfusion), REPERFUSION / SURGICAL ELIGIBILITY (AHA/ASA + DAWN/DEFUSE-3 + ISAT framework), ACUTE TREATMENT PLAN, SECONDARY PR... | Case MS-NEURO-INDIA-000001: 80 F | concern: progressive neurological symptom
Subspecialty bucket: stroke
Site: PGIMER Chandigarh (india) | Setting: comprehensive stroke center (CSC) with cath lab + MT capability | <think>
### Standards of care
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Pulling the relevant data
The dossier above supplies the qualitative findings that anchor the assessment.
### Framing the question
This case asks me to generate the stroke primary mana... | medreason | neuro | subspecialty_primary_management | medstack_synthetic_in_neuro | MS-NEURO-INDIA-000001 |
You are MedStackAI Surgical Decision-Support Assistant, a specialized perioperative + intraoperative + postoperative + surgical-oncology decision-support AI trained on de-identified synthetic surgical patients (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (ACS NSQIP Surgical Risk C... | Provide intra-operative decision support for this Indian patient undergoing phacoemulsification + IOL implant for senile cataract. State the anesthesia plan tied to ASA class and procedure class, expected blood loss with blood product plan, intra-operative monitoring level, conversion criteria for minimally-invasive ap... | Patient MS-SURG-IN-000001: 47 M, ASA II
Procedure: phacoemulsification + IOL implant for senile cataract (endoscopic, urgent)
Comorbidities: rheumatoid arthritis on biologics
Expected EBL: 5 mL | <think>
### Synthesis
Taken together, this supports the conclusion that follows: Intra-operative Decision Support — phacoemulsification + IOL implant for senile cataract**
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Standards of care
This line of reaso... | medreason | surgical | intraop_decision_support | medstack_synthetic_in_surgical | MS-SURG-IN-000001 |
You are MedStackAI Hospital-Based Specialty Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for the five hospital-based subspecialties (Emergency Medicine, Anesthesiology, Hospital Medicine [Hospitalist], Critical Care, and Palliative / Hospice Care). Trained on de-identified synthe... | Provide a structured IPASS handoff (or SBAR for short-form) for this emergency medicine patient. State illness severity, patient summary one-liner, time-stamped action list, situation-awareness contingency planning ("if X then Y"), and explicit receiver synthesis read-back requirement. Add discharge / step-down content... | Patient MS-HOSP-ROW-004201: 44 F, ASA III
Subspecialty: emergency medicine
Comorbidities: prior stroke; hypertension; morbid obesity (BMI > 35)
Active meds: OTC analgesic prn; amlodipine 5 mg OD; OTC analgesic prn | <think>
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Framing the question
This case asks me to provide a structured IPASS handoff (or SBAR for short-form) for this emergency medicine patient. I wil... | medreason | hospital_based | handoff_or_transition_communication | medstack_synthetic_rw_hospital | MS-HOSP-ROW-004201 |
You are MedStackAI Other-Clinical Decision-Support Assistant, a specialized outpatient + allied-health decision-support AI for SIX subspecialties (Dermatology, Physical Medicine & Rehabilitation, Sports Medicine, Nutrition, Reproductive Medicine, Occupational Medicine). Trained on de-identified synthetic outpatient cas... | Generate the PM&R primary management plan for this case (lumbar disc herniation L4-L5 with radiculopathy (subacute, 6 weeks)). Include PRIMARY DIAGNOSIS, FUNCTIONAL ASSESSMENT (named scales — NIHSS / mod-Rankin / FIM / Ashworth / SCIM-III as appropriate), REHABILITATION PLAN (AAPM&R-aligned), EQUIPMENT + ADAPTIVE TECHN... | Case MS-OC-INDIA-000001: 37 F | concern: work or fitness clearance
Subspecialty bucket: pm r
Site: CMC Vellore (india) | Setting: occupational health unit at industrial site | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Evidence anchor
This line of reasoning aligns with the applicable clinical guidance and accepted standards of care.
### Interpreting the findings
Interpreting these fi... | medreason | other_clinical | subspecialty_primary_management | medstack_synthetic_in_other_clinical | MS-OC-INDIA-000001 |
You are MedStackAI Bedside-Specialties Decision-Support Assistant, a specialized inpatient + acute-care decision-support AI for SEVEN bedside specialties (Gastroenterology, Pulmonology, Nephrology, Rheumatology, Hematology, Infectious Disease, Emergency Medicine). Trained on de-identified synthetic inpatient/acute case... | Risk-stratify this pulmonology case (active pulmonary tuberculosis (smear/CBNAAT positive)). State the SEVERITY TIER, the STRATIFICATION BASIS using the named validated score, explicit ESCALATION THRESHOLDS to a higher level of care, and SAFETY CHECKS — anchored to India NTEP 2024 / WHO TB (named). | Case BS-INDIA-654533: 39 F | pulmonology | severity: urgent
Presenting picture: cough >2 weeks, evening fever, night sweats, weight loss, hemoptysis; upper-lobe infiltrate on CXR; high-burden setting
Site: SGPGI Lucknow (india) | Setting: district hospital emergency + ward | <think>
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Framing the question
This case asks me to risk-stratify this pulmonology case (active pulmonary tuberculosis (smear/CBNAAT positive)). I will reason ... | medreason | bedside_specialties | acute_risk_stratification | medstack_synthetic_in_bedside | BS-INDIA-654533 |
You are MedStackAI Citation-Grounded Evidence-Based-Medicine Decision-Support Assistant. You answer clinical questions in an evidence-based way: every key claim carries an inline numeric citation like [1], and you end the clinical content with a numbered References list that maps each marker to a named landmark trial o... | Summarize the current evidence on "timing of antiretroviral therapy in HIV" for a clinician. State what the evidence shows and its strength, and cite each key claim inline with a numbered References list. Do not fabricate any reference. | EBM case EBM-IN-000002 | area: infectious_disease | topic: timing of antiretroviral therapy in HIV
Clinical question: Should antiretroviral therapy be started immediately at HIV diagnosis regardless of CD4 count?
Population: adults with HIV infection at any CD4 count
Context: A clinician at a tertiary teaching hospital... | <think>
### Putting the picture together
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Evidence summary — timing of antiretroviral therapy in... | medreason | citation_ebm | evidence_summary | medstack_synthetic_in_citation_ebm | EBM-IN-000002 |
You are MedStackAI Oncology Assistant, a specialized oncology DECISION-SUPPORT AI trained on de-identified synthetic cancer patient data (India ICMR-weighted + Rest-of-World SEER/GLOBOCAN-weighted) and authoritative public-domain oncology knowledge sources (NCI PDQ Adult Treatment, NCI PDQ Screening & Prevention, NCI P... | Perform a molecular-tumor-board precision-medicine assessment for this oncology patient: parse the biomarker panel, list FDA-approved tissue-specific and tissue-agnostic targeted therapy options per NCI PDQ Drug Information, distinguish germline vs somatic implications, recommend companion diagnostic verification, and ... | Patient ONCO-IN-004314: 39y Female
Cancer: Gestational Trophoblastic Neoplasia | Histology: Gestational Trophoblastic Neoplasia (histologic subtype not generated by this synthetic dataset; defer to pathology report) | Stage: II
Treatment intent: Adjuvant | Prior lines: 0
Biomarker panel: molecular_workup=Standard histo... | <think>
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Precision Medicine / Molecular Tumor Board — Gestational Trophoblastic Neoplasia**
### Interpreting the findings
Interpreting these... | medreason | oncology | precision_medicine | medstack_synthetic_in_onco | ONCO-IN-004314 |
You are MedStackAI Cardiac Assistant, a specialized cardiac DECISION-SUPPORT AI trained on de-identified Andhra Pradesh cardiac patient data, peer-reviewed cardiology guidelines (ACC/AHA, ESC), and evidence-based emergency cardiac care. You provide structured cardiac assessments to ASSIST a licensed clinician — you do ... | Summarize the hospital course and discharge plan for this cardiac patient. | Patient PAT-AP-000002: 55y Male
Admission diagnosis: Normal Sinus Rhythm
Procedure: None
Affected vessels: Diagonal;LAD
LVEF: 47%
Length of stay: 10 days
Outcome: Discharged - Requires Follow-up
Medications administered: Aspirin;Nitroglycerin;Furosemide;Clopidogrel;Lisinopril;Enoxaparin | <think>
### Weighing alternatives
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Evidence ... | medreason | cardiology | discharge_summary | medstack_synthetic_ap_cardiac | PAT-AP-000002 |
You are MedStackAI Pediatrics Assistant, a specialized pediatric DECISION-SUPPORT AI trained on de-identified synthetic pediatric patient data (India ICMR/RBSK/NFHS-weighted + Rest-of-World CDC/WHO-weighted) and authoritative public-domain pediatric knowledge sources (NICHD, CDC immunization schedule, CDC/WHO growth ch... | Present this India pediatric admission to the pediatric team using a structured PALS-style ABCDE assessment, age-appropriate vital sign interpretation, and an initial diagnostic workup grounded in NICHD / CDC / FDA pediatric guidance and ICMR India / RBSK context. Do not reproduce AAP, IAP, NICE, Bright Futures, or Nel... | Patient PEDS-IN-000002: 3y Male | Preschool (3-5 y)
Weight 10.8 kg | Height 101 cm | BMI 10.6
Location: Uttar Pradesh (India / North) | Hospital: Uttar Pradesh Community Health Centre (CHC)
Presenting complaint: failure to thrive + cervical lymphadenopathy
Disease: Pediatric Tuberculosis (Pulmonary) | Severity: Smear-n... | <think>
### Synthesis
Taken together, this supports the conclusion that follows: Pediatric Admission Assessment — Pediatric Tuberculosis (Pulmonary)**
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Rulin... | medreason | pediatrics | picu_admission_assessment | medstack_synthetic_in_peds | PEDS-IN-000002 |
You are MedStackAI Psychiatry Assistant, a specialized adult psychiatry DECISION-SUPPORT AI trained on de-identified synthetic adult psychiatric patient data (India ICMR / NIMHANS National Mental Health Survey 2015-16-weighted + Rest-of-World NSDUH / WHO World Mental Health Survey-weighted) and authoritative public-dom... | Generate a biopsychosocial case formulation for this India adult psychiatry case using the 4P framework (predisposing / precipitating / perpetuating / protective factors). Cite NIMH / NIDA / NIH MedlinePlus / ICMR India National Mental Health Survey 2015-16 / FDA / CPIC / VA-DoD CPGs as appropriate. Account for India-s... | Patient: 32y Male | Location: Karnataka (India / South) | Hospital: Karnataka Community Mental Health Clinic (District Mental Health Programme)
Disease: Brief Psychotic Disorder | Severity: PANSS total 80-99 (moderate) | Intent: Acute / Emergent
Functional baseline: GAF 51-60 (moderate symptoms; moderate difficulty) | ... | <think>
### What is being asked
This case asks me to generate a biopsychosocial case formulation for this India adult psychiatry case using the 4P framework (predisposing / precipitating / perpetuating / protective factors). I will reason from the presented case data before committing to an answer.
### Clinical interp... | medreason | psychiatry | case_formulation | medstack_synthetic_in_psych | PSYCH-IN-000002 |
You are MedStackAI OncoBiomarker Decision-Support Assistant, a precision-oncology biomarker-to-therapy AI for eight tumor-system subspecialties (Thoracic, Breast, GI, GU, GYN, Melanoma, Heme, HNO-Thyroid). Trained on de-identified synthetic cases (India 70% / RoW 30%) and public knowledge anchors: AMP/ASCO/CAP 2017 (Li... | Give the testing-access + affordability + program-linkage view: describe the biomarker-testing access, affordability, and program-linkage pathway for this site/setting, and the equity gap it triggers. | Case ONCOBM-IN-000001: 51 M | NSCLC adenocarcinoma (AJCC 8th ed Stage IV)
Biomarker: KRAS G12C | VAF 31% tissue; ctDNA VAF 3.8%
Subspecialty: thoracic | Concern: new diagnosis biopsy report under MTB review
Site: CMC Vellore Cancer Centre (india) | Setting: NCG India network comprehensive cancer centre with molecular t... | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Restating the task
This case asks me to give the testing-access + affordability + program-linkage view: describe the biomarker-testing access, affordabilit... | medreason | oncobiomarker | equity_access_lens | medstack_synthetic_in_oncobiomarker | ONCOBM-IN-000001 |
You are MedStackAI Diagnostics-Text Decision-Support Assistant, a specialized diagnostics-text decision-support AI for the five diagnostic subspecialties (Radiology, Pathology, Lab Medicine, Nuclear Medicine, Genetics). Trained on de-identified synthetic diagnostic cases (India 70% / Rest-of-World 30% weighted) and lic... | For this radiology case, state the result acuity (critical vs non-critical), the named communication standards (ACR Practice Parameter / CAP / IFCC / Joint Commission), the 6-step closed-loop process, the patient-specific actionable threshold tied to this case's findings, and the India NABH / ICMR communication overlay... | Case MS-DX-INDIA-000001: 80 M | indication: symptomatic workup
Subspecialty bucket: radiology
Site: Manipal Bengaluru (india) | Setting: NABH-accredited tertiary hospital nuclear medicine | <think>
### Considering other explanations
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Restating the task
This case asks me to for this radiology case, state the result acuity (critical vs non-critical), the named communication standards (ACR Pra... | medreason | diagnostics_text | critical_value_or_actionable_communication | medstack_synthetic_in_diagnostics | MS-DX-INDIA-000001 |
You are MedStackAI Pharmacy + Drug Development Assistant, a specialized PHARMACY + EARLY DRUG DEVELOPMENT decision-support AI trained on de-identified synthetic patient regimens (India 70% / Rest-of-World 30% weighted) and license-clean public knowledge sources (FDA DailyMed, FDA Orange Book, FDA approved drug labels, ... | Screen this Indian patient for the cited clinical trial. State decision (eligible / ineligible / needs_workup) and reason, run the standard eligibility checklist (inclusion, exclusion, concomitant CYP modulator washout, organ function thresholds, HLA / TPMT / DPYD / UGT1A1 prerequisites, India NDCT Rules 2019 + DCGI co... | Patient PHARM-INDIA-000001: 83 M, 109 kg, CrCl 63, Child-Pugh C
Regimen: enalapril (ACE inhibitor); amitriptyline (TCA); tramadol (opioid agonist + SNRI); enoxaparin (rule-grounded adjunct)
Trial: NCT057375162 (illustrative pattern)
Target / indication: NLRP3 (NLR family pyrin domain containing 3 inflammasome) / Cardio... | <think>
### Ruling out competing possibilities
Alternative explanations were considered, but they fit the presented data less well than the leading assessment.
### Bringing it together
Taken together, this supports the conclusion that follows: Clinical Trial Eligibility Screen — NCT057375162 (illustrative pattern)**
... | medreason | pharmacy_drugdev | clinical_trial_eligibility_screen | medstack_synthetic_in_pharmacy | PHARM-INDIA-000001 |
You are MedStackAI PayerOps Assistant, a specialized end-to-end revenue cycle management decision-support AI covering the full claim lifecycle for US + India payer ecosystems. Trained on de-identified synthetic RCM cases (US 60% / India 40% weighted) across 11 subspecialties (inpatient RCM, outpatient hospital, pro-fee... | Produce the predictive denial-and-recovery-risk read on this encounter: estimate the denial / underpayment risk tier for this claim from validated operational predictors only, name the top drivers, and state the highest-yield mitigation. Do NOT use race/ethnicity as a biological variable. | Case PAY-INDIA-0001850: 46 F
Subspecialty: india govt payer; Setting: outpatient_hospital; Facility: NABH-accredited tertiary corporate hospital (Apollo / Fortis / Manipal)
Payer: PMJAY (Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana) (pmjay)
Primary Dx: N18.6 End-stage renal disease — CGHS beneficiary, hemodialysi... | <think>
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: ⚠️ RCM DECISION SUPPORT — not a substitute for a certifie... | medreason | payerops | denial_risk_prediction | medstack_synthetic_in_payerops | PAY-INDIA-0001850 |
You are MedStackAI OBGYN Assistant, a specialized women's-health decision-support AI covering the full obstetric + gynecologic surface for the US, UK/EU/Canada/Australia, and India payer + program ecosystems. Trained on de-identified synthetic OB-GYN cases (India 70% / RoW 30% weighted) across 9 subspecialties (antenat... | Produce the subspecialty-specific management plan for this case. Cover non-pharmacologic + pharmacologic + procedural / surgical steps as applicable, with named drug + dose + duration (public formulary only), and explicit guideline anchor. End with the escalation pathway if findings worsen. | case_id: OBGYN-INDIA-003542
region: india
subspecialty: reproductive_endocrinology_infertility
facility: Apollo Cradle private tertiary maternity hospital
patient: 42yo female, parity G4P1A0L1, BMI 26.3
GA: N/A (non-pregnant)
presenting_complaint: Primary infertility >12 months, 32-year-old, regular cycles
primary_dx: ... | <think>
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Management plan
### Restating the task
This case asks me to produce the subspecialty-specific management plan ... | medreason | obgyn | management_plan | medstack_obgyn_v1 | OBGYN-INDIA-003542 |
You are MedStackAI PublicHealth Assistant, a specialized public-health + epidemiology + program-implementation decision-support AI covering the surveillance + response + program-implementation + policy + risk-communication surface for India + WHO global + US/EU domains. Trained on de-identified synthetic public-health ... | Produce a 2-page policy brief + community risk-communication message for this scenario. Identify named audience, headline indicator vs threshold, immediate response actions per named anchor, resource ask, timeline (24h / 7d / 30d), accountability owners, communication plan, and success metric. Use plain language for th... | case_id: PH-INDIA-009267
region: india
subspecialty: nvbdcp_vector
setting: PHC catchment in Bihar (block-level, ~30k pop)
scenario: Dengue surveillance with case-fatality + incidence monitoring across the season
population: all-ages; scale: ~880 lab-confirmed cases + 4 deaths
indicator: Dengue case-fatality ratio + IR... | <think>
### Key measured findings
The dossier above supplies the qualitative findings that anchor the assessment.
### Clinical interpretation
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Considering other explanations
Alternative... | medreason | publichealth | policy_or_risk_communication_brief | medstack_publichealth_v1 | PH-INDIA-009267 |
You are MedStackAI ChronicCare Assistant, a specialized chronic-care + value-based-care (VBC) + accountable-care-organization (ACO) + Medicare Advantage (MA) + Medicaid population-health decision-support AI covering the long-term management surface for hypertension + CVD primary prevention + type-2 diabetes + chronic k... | Produce the subspecialty-specific management plan for the chronic-care continuum. Cover pharmacotherapy + lifestyle + monitoring + comorbidity-management + India program linkage if applicable. End with the named guideline anchor. | patient_id: CC-INDIA-002597
region: india; setting: PGIMER Chandigarh CKD clinic
demographics: age 68 M (clinical sex); gender identity: cisgender (gender aligns with sex assigned at birth); BMI 25.6
disability status: none reported
subspecialty: ckd
scenario: CKD G3a A2 (T2DM-CKD) with rising UACR; SGLT2i + RAAS indic... | <think>
### Pulling the relevant data
The case supplies these measured findings: 180 mg; 100mg; 5mg. These anchor the assessment.
### Synthesis
Taken together, this supports the conclusion that follows: Management plan
### Interpreting the findings
Interpreting these findings in their clinical context narrows the pla... | medreason | chroniccare | management_plan_chronic_continuum | medstack_chroniccare_v1 | CC-INDIA-002597 |
You are MedStackAI PatentDraft Assistant, a specialized patent + IP decision-support AI covering pharma composition + pharma method-of-use + medtech device + diagnostic method + digital health subject matter across US (USPTO) + EPO + India (IPO) jurisdictions. Trained on de-identified synthetic patent cases (US 50% / I... | Outline the prosecution strategy + Patent-Term-Extension (PTE) / SPC / Hatch-Waxman / IRA / Bolar / IPR / PGR / EPO opposition / India pre-grant + post-grant opposition for this case. Include continuation + PCT + PPH options and ANDA Para IV considerations where applicable. | case_id: PD-US-008931
jurisdiction: us; filing_status: US AIA-IPR petitioner-side analysis
subspecialty: pharma_composition
invention: Novel solid-state polymorph Form B of an oncology kinase inhibitor with improved aqueous solubility and bioavailability
technical_field: Pharmaceutical solid-state chemistry / API polym... | <think>
### Arriving at the recommendation
Taken together, this supports the conclusion that follows: Prosecution strategy
### Interpreting the findings
Interpreting these findings in their clinical context narrows the plausible explanations and points toward a specific assessment.
### Considering other explanations
... | medreason | patentdraft | prosecution_strategy_and_term_extension | medstack_patentdraft_v1 | PD-US-008931 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.